[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 138
1. Sträter J, Herter I, Merkel G, Hinz U, Weitz J, Möller P: Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis. Int J Cancer; 2010 Aug 15;127(4):873-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
  • To study their prognostic influence in colon carcinoma, expression of APAF-1, caspase-8 and caspase-9 was determined by immunohistochemistry in normal colon mucosa (n = 8) and R0-resected stage II/III colon carcinomas (n >or= 124) using a semiquantitative score.
  • In normal colon, APAF-1 and caspase-8 are most strongly expressed in the luminal surface epithelium, whereas caspase-9 is expressed all along the crypt axis.
  • In colon carcinomas, there is considerable variability in the expression of these proapoptotic factors, although complete loss of caspase-8 and caspase-9 is rare.
  • The influence of caspase-8 expression was mainly seen in patients with stage III colon carcinoma (p = 0.011), whereas the prognostic influence of caspase-9 expression was significant in stage II cases (p = 0.037) and just failed to be significant in stage III tumors (p = 0.0581).
  • Our data suggest that, in colon carcinomas, expression of caspase-8 and caspase-9 is significantly associated with poor survival.
  • Caspase-9 may be an independent prognosticator in colon carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma, Mucinous / metabolism. Apoptotic Protease-Activating Factor 1 / metabolism. Biomarkers, Tumor / metabolism. Caspase 8 / metabolism. Caspase 9 / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Colon / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013803.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / APAF1 protein, human; 0 / Apoptotic Protease-Activating Factor 1; 0 / Biomarkers, Tumor; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9
  •  go-up   go-down


2. Wang W, Li YF, Sun XW, Chen G, Zhan YQ, Huang CY, Wan DS, Pan ZZ, Zhou ZW: Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients. Chin J Cancer; 2010 Aug;29(8):761-7
Genetic Alliance. consumer health - Chromosome 18q-.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation analysis between loss of heterozygosity at chromosome 18q and prognosis in the stage-II colon cancer patients.
  • In this study we detected the frequency of loss of heterozygosity (LOH) at chromosome 18q and investigated the relationship between LOH and clinicopathologic features and its prognostic value for patients with stage II colon cancer.
  • METHODS: A total of 106 samples of tumor tissues and corresponding normal mucosa from patients with sporadic stage-II colon cancer were included in this study.
  • Multivariate analysis for association between LOH and prognosis in colon cancer patients was performed with Cox proportional hazards regression model.
  • LOH was more frequent on the left-side, poorly-differentiated adenocarcinoma, and nonmucinous colon cancers.
  • The occurrence of 18q-LOH is an independent poor prognostic factor for the patients with stage-II colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 18 / genetics. Colonic Neoplasms / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adenocarcinoma, Mucinous / genetics. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Papillary / genetics. Adenocarcinoma, Papillary / pathology. Adenocarcinoma, Papillary / surgery. Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Grading. Neoplasm Staging. Proportional Hazards Models. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20663324.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ, Kruhøffer M, Laurberg S, Kauppinen S, Ørntoft TF, Andersen CL: Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res; 2008 Aug 1;68(15):6416-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic microRNAs in stage II colon cancer.
  • Here, we used microarrays to profile the expression of 315 human miRNAs in 10 normal mucosa samples and 49 stage II colon cancers differing with regard to microsatellite status and recurrence of disease.
  • We successfully verified the expression of selected miRNAs using real-time reverse transcription-PCR assays for mature miRNAs, whereas in situ hybridization was used to detect the accumulation of miR-145 and miR-320 in normal epithelial cells and adenocarcinoma cells.
  • Functional studies showed that miR-145 potently suppressed growth of three different colon carcinoma cell lines.
  • In conclusion, our results suggest that perturbed expression of numerous miRNAs in colon cancer may have a functional effect on tumor cell behavior, and, furthermore, that some miRNAs with prognostic potential could be of clinical importance.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterology. 2009 Mar;136(3):1112-4; discussion 1114 [19167396.001]
  • (PMID = 18676867.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MIRN498 microRNA, human; 0 / MicroRNAs
  •  go-up   go-down


Advertisement
4. Blum C, Graham A, Yousefzadeh M, Shrout J, Benjamin K, Krishna M, Hoda R, Hoda R, Cole DJ, Garrett-Mayer E, Reed C, Wallace M, Mitas M: The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer. Int J Oncol; 2008 Sep;33(3):579-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer.
  • The tumor samples were extracted from formalin-fixed paraffin-embedded primary tissues derived from patients with Stage II CRC who developed disease recurrence within two years (n=10), or were disease-free for at least 4 years (n=12).
  • This suggests that the expression ratio of Map7/B2M may serve as a valuable prognostic marker in patients with Stage II colon cancer, and potentially guide therapeutic decision making.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1332-42 [10837026.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):887-95 [17235506.001]
  • [Cites] CA Cancer J Clin. 1999 Jul-Aug;49(4):202-19 [11198882.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):719-25 [14766275.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):607-16 [15193263.001]
  • [Cites] J Immunol. 1989 Jan 1;142(1):352-8 [2462591.001]
  • [Cites] J Exp Med. 1989 Jan 1;169(1):309-14 [2642530.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Cancer Res. 1992 Mar 1;52(5):1201-4 [1737380.001]
  • [Cites] J Cell Biol. 1995 Nov;131(4):1015-24 [7490279.001]
  • [Cites] Tumori. 1997 Jan-Feb;83(1 Suppl):S39-41 [9154066.001]
  • [Cites] Inflamm Bowel Dis. 1998 Aug;4(3):196-202 [9741021.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2080-7 [16609019.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2849-54 [17504982.001]
  • [Cites] CA Cancer J Clin. 2007 May-Jun;57(3):168-85 [17507442.001]
  • [Cites] Biotechniques. 2000 Sep;29(3):548-50, 552-4, 556 passim [10997270.001]
  • (PMID = 18695889.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA093419; United States / NCI NIH HHS / CA / R21 CA097875; United States / NCI NIH HHS / CA / R33 CA097875; United States / NCI NIH HHS / CA / CA097875
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Microtubule-Associated Proteins; 0 / beta 2-Microglobulin
  • [Other-IDs] NLM/ NIHMS388523; NLM/ PMC3399116
  •  go-up   go-down


5. Barrier A, Roser F, Boëlle PY, Franc B, Tse C, Brault D, Lacaine F, Houry S, Callard P, Penna C, Debuire B, Flahault A, Dudoit S, Lemoine A: Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene; 2007 Apr 19;26(18):2642-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.
  • We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients.
  • In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Cluster Analysis. Female. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17043639.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger GG, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, Austrian Breast and Colorectal Cancer Study Group: A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer; 2007 Oct 22;97(8):1021-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
  • The purpose of this trial was to investigate the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in stage II colon cancer.
  • Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only.
  • In conclusion, results of this trial demonstrate a trend to a lower risk for relapse in patients treated with adjuvant 5-FU/LV for stage II colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3553-9 [10550154.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):602-10 [16998369.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Biometrics. 1975 Mar;31(1):103-15 [1100130.001]
  • [Cites] J Natl Cancer Inst. 1988 Mar 2;80(1):30-6 [3276901.001]
  • [Cites] Arch Surg. 1989 Feb;124(2):180-2 [2916939.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1466-75 [2202789.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1879-87 [8410113.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • (PMID = 17895886.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2360441
  •  go-up   go-down


7. Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Landmann RG, Guillem JG, Paty PB, Temple LK, Wong WD, Weiser MR: Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum; 2008 May;51(5):503-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of patients with high-risk stage II colon cancer for adjuvant therapy.
  • PURPOSE: Adjuvant therapy for Stage II colon cancer remains controversial but may be considered for patients with high-risk features.
  • The purpose of this study was to assess the prognostic significance of commonly reported clinicopathologic features of Stage II colon cancer to identify high-risk patients.
  • METHODS: We analyzed a prospectively maintained database of patients with colon cancer who underwent surgical treatment from 1990 to 2001 at a single specialty center.
  • We identified 448 patients with Stage II colon cancer who had been treated by curative resection alone, without postoperative chemotherapy.
  • Univariate and multivariate analyses identified three independent features that significantly affected disease-specific survival: tumor Stage T4 (hazard ratio (HR), 2.7; 95 percent confidence interval (CI), 1.1-6.2; P = 0.02), preoperative carcinoembryonic antigen > 5 ng/ml (HR, 2.1; 95 percent CI, 1.1-4.1; P = 0.02), and presence of lymphovascular or perineural invasion (HR, 2.1; 95 percent CI, 1-4.4; P = 0.04).
  • CONCLUSIONS: Patients with Stage II colon cancer generally have an excellent prognosis.
  • Use of commonly reported clinicopathologic features accurately stratifies Stage II colon cancer by disease-specific survival.
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322753.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Phelip JM, Molinié F, Delafosse P, Launoy G, Trétarre B, Bara S, Buémi A, Velten M, Danzon A, Ganry O, Bouvier AM, Grosclaude P, Faivre J: A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers. Gastroenterol Clin Biol; 2010 Feb;34(2):144-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based study of adjuvant chemotherapy for stage-II and -III colon cancers.
  • BACKGROUND: Although clinical trials have demonstrated that adjuvant chemotherapy improves survival for stage-III colon cancer, the benefits remain controversial for stage-II lesions.
  • The objective of the present study was to determine the extent to which adjuvant chemotherapy is used for patients with stage-II and -III colon cancers.
  • METHODS: The study population comprised 1074 patients with stage-II and -III colon cancers diagnosed in 2000 in 12 French administrative districts and recorded in population-based cancer registries.
  • RESULTS: Overall, 20.4% of patients with stage II and 61.9% with stage III received adjuvant chemotherapy.
  • Among stage-II patients, those receiving chemotherapy decreased from 57.6% in patients aged <or=50 years to 1.1% in those aged >or=85.
  • The corresponding percentages with stage III were 93.6% and 1.4%.
  • In multivariate analyses, other factors found to be independently and significantly associated with administration of adjuvant chemotherapy for stage II were extension of the cancer (stage IIA vs. stage IIB), clinical presentation (obstruction or perforation vs. uncomplicated cancer) and discussion of the case at a multidisciplinary case-review meeting.
  • For stage III, apart from age, discussion of the case at a multidisciplinary meeting was the only factor independently associated with administration of chemotherapy.
  • CONCLUSION: Adjuvant chemotherapy for stage-III colon cancer is used extensively for patients under 75 years of age.
  • On the other hand, a substantial percentage of stage-II colon cancer patients receive adjuvant chemotherapy despite its uncertain benefits.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Colonic Neoplasms / drug therapy. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20079591.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Muc-Wierzgon M, Nowakowska-Zajdel E, Kokot T, Kozowicz A, Wiczkowski A, Grochowska-Niedworok E, Mazurek U, Wierzgon J: Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease. J Biol Regul Homeost Agents; 2006 Jan-Jun;20(1-2):10-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease.
  • The expression of the genes coding TNFalpha and TNF RII receptors (TNF RII: TNFR2 membrane and soluble domain, TNFR2/R7 soluble domain) was analysed in colon cancer at the II and III stage of disease, by estimation of mRNA expression.
  • The study included 80 patients with histopathologically confirmed adenocarcinoma.
  • The highest number of mRNA TNF-alpha copies were investigated in all samples of tissue and independently of the stage of disease.
  • Simultaneously, we noticed the largest number of mRNA copies for TNFalpha and TNF R2/R7 in healthy cells at stage III of the disease.
  • [MeSH-major] Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Gene Expression Regulation, Neoplastic / genetics. Receptors, Tumor Necrosis Factor, Type II / genetics. Tumor Necrosis Factor-alpha / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18088549.001).
  • [ISSN] 0393-974X
  • [Journal-full-title] Journal of biological regulators and homeostatic agents
  • [ISO-abbreviation] J. Biol. Regul. Homeost. Agents
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Tumor Necrosis Factor, Type II; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


10. Chin CC, Wang JY, Changchien CR, Huang WS, Tang R: Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor. Int J Colorectal Dis; 2010 Jul;25(7):817-22
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor.
  • PURPOSE: Colon obstruction is suggested to be a predictor of poor outcome in colon cancer.
  • However, the effect of obstruction on outcome in patients with different tumor-nodes-metastases (TNM) stage cancer has not been fully addressed.
  • The aim of this study is to determine whether colon obstruction predicts surgical and long-term oncologic outcomes in patients with proximal colon cancer.
  • METHODS: A total of 1,492 consecutive patients underwent open resection of primary adenocarcinoma of right colon in a single institution between January 1995 and December 2005.
  • Univariate and multivariate analyses were performed to identify colon obstruction and other predictors of surgical and oncologic outcomes.
  • RESULTS: Among 1,492 patients, 306 (20.5%) patients presented with colon obstruction.
  • Obstruction predicted a worse long-term disease-free survival (DFS) among patients with stage II-III disease (log-rank test, p = 0.0003).
  • The data were stratified by TNM stage.
  • Obstruction predicted a worse DFS among patients with TNM stage II cancer (598 patients; log-rank test, p = 0.001; Cox regression, p = 0.012), but it was not a predictor in TNM stage III cancer patients (424 patients; p = 0.116; p = 0.108).
  • CONCLUSIONS: Colon obstruction was an independent predictor of long-term outcome only in TNM stage II but not in stage III proximal colon cancer.
  • Patients with TNM stage II obstructive colon cancer could be included in future trials of adjuvant therapies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surgery. 2000 Apr;127(4):370-6 [10776426.001]
  • [Cites] Int J Colorectal Dis. 2009 Jun;24(6):665-76 [19238405.001]
  • [Cites] Am J Surg. 2004 Apr;187(4):497-500 [15041498.001]
  • [Cites] Eur J Cancer. 1996 Feb;32A(2):295-302 [8664045.001]
  • [Cites] Colorectal Dis. 2008 Jan;10(1):33-40 [17672872.001]
  • [Cites] Ann Surg. 1983 Dec;198(6):743-52 [6357118.001]
  • [Cites] Hepatogastroenterology. 2008 Jul-Aug;55(85):1288-92 [18795674.001]
  • [Cites] Br J Surg. 1989 Sep;76(9):965-9 [2804601.001]
  • [Cites] Br J Surg. 1986 Aug;73(8):663-70 [3742184.001]
  • [Cites] Rev Med Chil. 2004 Jun;132(6):691-700 [15332370.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):887-98 [16614880.001]
  • [Cites] J Surg Oncol. 1991 Jul;47(3):188-92 [2072703.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):108-13 [12520705.001]
  • [Cites] Br J Surg. 2006 Apr;93(4):483-8 [16555262.001]
  • [Cites] Lancet. 1986 Oct 18;2(8512):904-7 [2876336.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Br Med J. 1979 Sep 1;2(6189):515-7 [497669.001]
  • [Cites] Br J Surg. 1985 Apr;72(4):296-302 [3986481.001]
  • [Cites] Dis Colon Rectum. 1991 Sep;34(9):759-62 [1914740.001]
  • [Cites] Dis Colon Rectum. 1997 Mar;40(3):326-31 [9118749.001]
  • (PMID = 20135321.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Jacob BP, Salky B: Laparoscopic colectomy for colon adenocarcinoma: an 11-year retrospective review with 5-year survival rates. Surg Endosc; 2005 May;19(5):643-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for colon adenocarcinoma: an 11-year retrospective review with 5-year survival rates.
  • BACKGROUND: Laparoscopic colectomy for the management of colon cancer remains a controversial therapeutic option, especially when the outcomes are compared with the historically accepted survival data and recurrence rates after open surgery.
  • The purpose of this study was to evaluate the 5-year overall and disease-free survival rates after laparoscopic colon resection for invasive colon adenocarcinoma.
  • METHODS: A total of 129 patients underwent consecutive laparoscopic colectomies for colon adenocarcinoma (between April 1992 and 2004 January) by a single surgeon at a single institution.
  • RESULTS: After patients with noninvasive disease on final pathology were excluded, the study population comprised 88 patients who underwent laparoscopic colectomies for invasive colon cancer with > 2 years of follow-up.
  • The Kaplan-Meier survival data were as follows for 5-year overall survival and 5-year disease-free survival, respectively stage I (n = 34) 89% and 89%; stage II (n = 22), 65% and 59%; stage III (n = 19), 72% and 67%; stages I-III combined, (n = 75), 77% and 73%.
  • CONCLUSIONS: For this specific cohort of patients undergoing curative laparoscopic colectomies for invasive colon adenocarcinoma, the mean follow-up was > 5 years.
  • Overall survival and disease-free survival for stage I, II, and III colon cancer as well as for stages I-III combined are favorable and comparable to historically acceptable open colectomy survival rates.
  • Overall survival and disease-free survival after laparoscopic colectomy for invasive colon cancer is no worse, and perhaps better than, the previously reported rates for the same procedure done by an open technique.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Neoplasms / surgery. Laparoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2006 Jun;20(6):996-7 [16739001.001]
  • [Cites] Br J Surg. 1995 Mar;82(3):295-8 [7795990.001]
  • [Cites] World J Surg. 1993 Jan-Feb;17(1):51-6 [8447141.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S53-8 [8831547.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S20-3 [8831542.001]
  • [Cites] Dis Colon Rectum. 1996 Feb;39(2):155-9 [8620781.001]
  • [Cites] J Surg Oncol. 1998 Aug;68(4):255-67 [9721713.001]
  • [Cites] Dis Colon Rectum. 1983 Sep;26(9):571-2 [6223795.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):601-11 [12792435.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]
  • [Cites] Surg Endosc. 1996 Nov;10(11):1041-4 [8881048.001]
  • [Cites] Ann Surg. 1992 Dec;216(6):703-7 [1466626.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S35-46 [8831545.001]
  • [Cites] Dis Colon Rectum. 1996 Feb;39(2):148-54 [8620780.001]
  • [Cites] Dis Colon Rectum. 1996 Feb;39(2):200-7 [8620788.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):590-606 [11685021.001]
  • [Cites] Surg Endosc. 2002 Oct;16(10):1409-12 [12140622.001]
  • [Cites] Surg Oncol. 2000 Nov;9(3):127-34 [11356341.001]
  • (PMID = 15789256.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Lenehan PF, Fry DW, Heyman ER, Eliason JF, Worzel WP: Generation and validation of a primary-tumor-derived four-gene prognostic signature for recurrence (R) of stages I/II colorectal cancer (CRC) following potentially curative resection. J Clin Oncol; 2009 May 20;27(15_suppl):4035

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Generation and validation of a primary-tumor-derived four-gene prognostic signature for recurrence (R) of stages I/II colorectal cancer (CRC) following potentially curative resection.
  • : 4035 Background: Current guidance for postoperative clinical management of stages I/II CRC patients (pts) is suboptimal.
  • METHODS: Archival formalin-fixed paraffin-embedded (FFPE) primary adenocarcinoma tissues obtained at initial resection with curative intent were retrieved for 145 stage I/II (pT1-4 pN0 M0) CRC pts from multiple international sites; none had neoadjuvant or adjuvant therapy.
  • RR by stage (I/II) = 7.00/7.28 and tumor site (colon/rectum) = 8.75/4.50.
  • CONCLUSIONS: A GP derived 4-gene prognostic test using FFPE tumor tissue can differentiate early stage CRC pts at high versus low risk for R within 3y better than current NCCN Guidelines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Perazzo F, Denninghoff V, Pasccon G, Pallotta MG, Tatangelo M, Cuartero V, Kirchuck R, Chacón M, Gennari L, Vera K, Avagnina A: Preliminary report of the mutation status of KRAS and BRAF-V600E in an Argentinean population of primary colorectal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22183

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary tumor site was 21.9% (32) right colon, 5.5% (8) transverse colon, 45.2% (66) left colon and 27.4%(40) rectal cancer.
  • Adenocarcinoma was the unique histotype and mucinous differentiation was observed in 14.7% (21).
  • The Pathological Stage at diagnosis was Stage I 3.42% (5), II 24% (35), III 33.6% (49) and IV 39% (57).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Overman MJ, Hu C, Wolff RA, Chang GJ: Impact of lymph node evaluation on survival for small bowel adenocaricnoma: Analysis of the Surveillance, Epidemiology and End Results (SEER) database. J Clin Oncol; 2009 May 20;27(15_suppl):4596

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4596 Background: Small bowel adenocarcinoma is a rare malignancy and is often associated with poor outcome.
  • METHODS: Patients aged 18-90 with adenocarcinoma of the small intestine diagnosed between 1988 and 2005 were identified from SEER data (ver. 2008).
  • Cox proportional hazards regression analyses were performed after adjusting for age, sex, race, T stage, grade, and primary site.
  • Stage I-II cases were categorized by total LN examined (1-8, 9-12, and >12).
  • Stage III cases were evaluated using cut-point analysis to determine the number of positive LN that predicted outcomes.
  • Survival among stage I/II patients (n=1,216) was dependent upon the total number of LN assessed.
  • 5-year DSS for stage II patients was 66%, 82% (HR 0.52 95% CI .33-.84), and 88% (HR 0.38, 95% CI .23-.61) for 1-8, 9-12, >12 LN, respectively.
  • The optimal cutpoint of positive LN for stage III disease (n=775) was <3 compard to ≥3 with 5 year DSS of 58% vs. 37% (HR 1.49, 95% CI 1.15-1.92, P=0.002), respectively.
  • Among stage III patients, the LNR was even more predictive of survival than stratification by the number of positive lymph nodes as demonstrated by an improved chi-square statistic for the multivariate model (78.8 vs 63.1, P=0.0005).
  • CONCLUSIONS: As noted in colon cancer, the total number of LN assessed has considerable influence upon survival in stage I, II and III small bowel adenocarcinoma.
  • Stratifying stage III small bowel adenocarcinoma into those with <3 and ≥3 positive lymph nodes significantly improves prognostication for these patients and future staging systems should incorporate the number of positive nodes into nodal staging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963112.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Kim J, Chae Y, Sohn S, Kang B, Lee S, Lim K, Choi G, Baek J: -93G&gt;A polymorphism of hMLH1 associated with prognosis for patients with colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4039

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Three hundred and ninety- seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study.
  • RESULTS: The median age of the patients was 63 years (range, 21-85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer.
  • Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%).
  • Multivariate survival analysis including stage, differentiation, age, and CEA level showed that the survival for the patients with the -93AA genotype of hMLH1 was worse than for the patients with the combined -93GG and GA genotype (overall survival: hazard ratio [HR]=2.953, 95% Confidential Interval [CI], 1.273-6.850, P=0.012; disease-free survival: HR=2.299, 95% CI, 1.417-3.730, P=0.001), whereas the other polymorphisms were not associated with survival.
  • Accordingly, in addition to the pathologic stage, the analysis of -93G>A polymorphism of hMLH1 can help identify patient subgroups at high risk of a poor disease outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961540.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Bayraktar UD, Bayraktar S, Herna S, Ku N, Jones C, Merchan J, Sands LR, Marchetti F, Montero A, Rocha-Lima CM: Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer? J Clin Oncol; 2009 May 20;27(15_suppl):4046

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does delay of adjuvant chemotherapy affect the clinical outcome in patients with colon cancer?
  • : 4046 Background: Adjuvant chemotherapy (AC) in patients with stage III colon adenocarcinoma prevents recurrences and improves survival.
  • We hypothesized that AC commenced within 60 days of resection would increase survival in patients with stage II and III colon cancer.
  • METHODS: Patients with newly diagnosed stage II or III colon adenocarcinoma who received fluoropyrimidine based AC in two centers (a private cancer center and a large community hospital) between 2000 and 2007 were included into analysis.
  • 116 patients (61%) were female and 35 patients (18%) had stage II disease.
  • The only difference between the two groups was the higher N stage in group 1.
  • The treating hospital and the N stage were found to be the factors affecting the OS in univariate analysis.
  • Five-year OS for group I was 75.2% as compared to 61.3% for group II (HR 2.11, CI: 1.00-4.45, p=0.049).
  • Five-year RFS for group I was 65.7% as compared to 59.0% for group II (HR: 1.19, CI: 0.65-2.20, p=0.570).
  • CONCLUSIONS: Delay of AC more than 60 days after resection is associated with inferior survival in stage II/III colon cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961564.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chung KY, Kelsen D: Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What? Curr Treat Options Gastroenterol; 2006 Jun;9(3):272-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant Therapy for Stage II Colorectal Cancer: Who and with What?
  • The role of adjuvant chemotherapy for patients with stage II colon adenocarcinoma remains controversial.
  • The high surgical cure rate for patients with "low-risk" stage II colon cancer, ranging from 75% to 80%, and the available clinical trials and meta-analyses provide conflicting recommendations for or against adjuvant chemotherapy for this group of patients.
  • For fit "high-risk" stage II patients with clinical obstruction or perforation at presentation, in which the 5-year survival rate is 60% to 70%, there is little controversy, as these patients are routinely treated with adjuvant chemotherapy.
  • These patients may have stage III disease and should receive adjuvant therapy.
  • The decision to use adjuvant chemotherapy to treat low-risk stage II colon cancer patients (no obstruction or perforation) should be an informed decision weighing the magnitude of a net 2% to 5% survival benefit, a 0.5% to 1.0% risk of mortality with chemotherapy in addition to 6 months of chemotherapy-related toxicities, other coexisting patient morbidities, and the anticipated life expectancy of each patient.
  • As adjuvant chemotherapy is therapy addressing local or metastatic microscopic disease, and the effectiveness of systemic and biologically targeted therapy for advanced macroscopic colon cancer continues to improve rapidly, it remains to be determined by clinical trials whether therapies including newer agents such as cetuximab and bevacizumab administered in the adjuvant setting may affect survival for stage II cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901391.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Asaad SM, Jubelirer SJ, Welch CA: Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon. W V Med J; 2005 Sep-Oct;101(5):210-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic indicators for stage II (Dukes' stage B) adenocarcinoma of the colon.
  • To determine the prognostic indicators that are associated with lower disease free survival (DFS) and overall survival (OS) in stage II colon cancer patients, the tumor registry records were reviewed for all patients diagnosed with stage II and III adenocarcinoma of the colon at Charleston Area Medical Center from 1986 to 1994.
  • The prognostic indicators of 174 stage II patients who had not undergone treatment were assessed for DFS and OS.
  • In addition, DFS and OS curves for stage II patients with < 7 LNR were not significantly different from survival curves for stage III patients.
  • Treatment decisions are made based primarily on stage, and stage II patients are not routinely offered adjuvant therapy.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16422269.001).
  • [ISSN] 0043-3284
  • [Journal-full-title] The West Virginia medical journal
  • [ISO-abbreviation] W V Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Weissenberger C, Geissler M, Otto F, Barke A, Henne K, von Plehn G, Rein A, Muller C, Bartelt S, Henke M: Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002). World J Gastroenterol; 2006 Mar 28;12(12):1849-58
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).
  • METHODS: Two hundred and eighty-six patients with Union International Contre Cancer (UICC) stage II and III rectal adenocarcinomas, who underwent resection by conventional surgical techniques (low anterior or abdominoperineal resection), received either postoperative (n=233) or preoperative (n=53) radiochemotherapy from January 1989 until July 2002.
  • RESULTS: Anemia before radiochemotherapy was an independent prognostic factor for improved DFS (risk ratio 0.76, P=0.04) as well as stage, grading, R status (free radial margins), type of surgery, carcinoembryonic antigen (CEA) levels, and gender.
  • Stage, grading, R status (free radial margins), type of surgery, CEA levels, and gender have predictive value for the outcome of rectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Anemia / etiology. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):45-51 [14704844.001]
  • [Cites] Dis Colon Rectum. 1992 Nov;35(11):1057-65 [1425050.001]
  • [Cites] World J Surg. 1992 Sep-Oct;16(5):858-65 [1462620.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Dis Colon Rectum. 1993 Jun;36(6):564-72 [8500374.001]
  • [Cites] Dis Colon Rectum. 1994 Jan;37(1):73-87 [8287751.001]
  • [Cites] Am J Clin Oncol. 1995 Aug;18(4):277-81 [7625365.001]
  • [Cites] Int J Colorectal Dis. 1995;10(3):126-32 [7561427.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):305-11 [9069301.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):352-7 [9117306.001]
  • [Cites] Anticancer Res. 1997 Mar-Apr;17(2B):1379-82 [9137502.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):866-7 [9221868.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4B):2935-8 [9329568.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174 Suppl 4:31-4 [9879345.001]
  • [Cites] Langenbecks Arch Surg. 1998 Dec;383(6):416-26 [9921941.001]
  • [Cites] Ann Surg. 1999 Oct;230(4):544-52; discussion 552-4 [10522724.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2412-8 [10561304.001]
  • [Cites] Cancer. 1999 Nov 15;86(10):1952-8 [10570418.001]
  • [Cites] Int J Biol Markers. 2000 Jan-Mar;15(1):51-5 [10763141.001]
  • [Cites] Int J Colorectal Dis. 2000 Feb;15(1):9-20 [10766086.001]
  • [Cites] Curr Opin Oncol. 2001 Jul;13(4):300-6 [11429489.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3895-902 [11559727.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Br J Surg. 1984 Jan;71(1):12-6 [6689962.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] N Engl J Med. 2001 Oct 11;345(15):1091-7 [11596588.001]
  • [Cites] Rev Invest Clin. 2001 Sep-Oct;53(5):388-95 [11795103.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1744-50 [11919230.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1751-8 [11919231.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):919-36 [11978517.001]
  • [Cites] Am Surg. 2002 May;68(5):482-7 [12013294.001]
  • [Cites] Am J Surg. 2002 May;183(5):504-8 [12034381.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):386-96 [12243812.001]
  • [Cites] Eur J Cancer Care (Engl). 2002 Sep;11(3):166-72 [12296832.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):329-35 [12385573.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):1035-58 [12507208.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):549-57 [1548520.001]
  • (PMID = 16609990.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC4087509
  •  go-up   go-down


20. Read TE, Fleshman JW, Caushaj PF: Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy. Dis Colon Rectum; 2005 Jan;48(1):80-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node mapping for adenocarcinoma of the colon does not improve staging accuracy.
  • PURPOSE: This study was designed to: determine the efficacy of sentinel lymph node mapping in patients with intraperitoneal colon cancer; and create an algorithm to predict potential survival benefit by using best-case estimates in favor of sentinel node mapping and lymph node ultraprocessing techniques.
  • METHODS: Forty-one patients with intraperitoneal colon cancer undergoing colectomy with curative intent were studied prospectively.
  • After mobilization of the colon and mesentery, 1 to 2 ml of isosulfan blue dye was injected subserosally around the tumor.
  • Stage of disease in the remaining 38 patients was: I, n = 10 (26 percent); II, n = 15 (39 percent); III, n = 11 (29 percent); IV, n = 2 (5 percent).
  • To create a survival benefit algorithm, we assumed the following: combined fraction of Stage I and II disease (0.5); fraction understaged by bivalving and hematoxylin and eosin staining that would have occult positive nodes by more sophisticated analysis (0.15); fraction of occult positive nodes detected by sentinel node mapping (0.9); and survival benefit from chemotherapy (0.33).
  • CONCLUSIONS: Sentinel node mapping with isosulfan blue dye and routine processing of retrieved nodes does not improve staging accuracy in patients with intraperitoneal colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Algorithms. Colonic Neoplasms / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690662.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV, Mayer RJ: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol; 2005 Dec 1;23(34):8671-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
  • PURPOSE: In 1990, fluorouracil (FU) plus levamisole for 1 year became standard adjuvant treatment for patients with high-risk stages II and III colon cancer.
  • INT-0089 has long-term follow-up of the largest clinical trial of patients with high-risk colon cancer, documenting not only the durability of the treatment effects, but also the natural history of patients with high-risk colon cancer, and analyses of treatment based on age, race, and comorbid conditions such as obesity, diabetes, and second primary cancers.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314627.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA15488; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / CA66636
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 12001-76-2 / Vitamin B Complex; 2880D3468G / Levamisole; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Yamamoto S, Kawahara K, Maekawa T, Shiraishi T, Shirakusa T: Minimally invasive esophagectomy for stage I and II esophageal cancer. Ann Thorac Surg; 2005 Dec;80(6):2070-5
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive esophagectomy for stage I and II esophageal cancer.
  • The histologic type of cancer was squamous cell carcinoma in 109 (97.4%) patients and adenocarcinoma in 3 (2.6%).
  • Induction chemoradiotherapy, preoperative concomitant disease, and reconstruction using the colon did not increase morbidity.
  • For stage I disease, the 5-year survival rate of patients was 87.2%.
  • In stage II disease, it was 70.2%.
  • The survival of patients with stage I and II disease is satisfactory at the present time.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / pathology. Esophageal Neoplasms / surgery. Esophagectomy / methods. Thoracic Surgery, Video-Assisted

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16305846.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


23. Ginty F, Adak S, Can A, Gerdes M, Larsen M, Cline H, Filkins R, Pang Z, Li Q, Montalto MC: The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer. Clin Cancer Res; 2008 Jun 15;14(12):3814-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relative distribution of membranous and cytoplasmic met is a prognostic indicator in stage I and II colon cancer.
  • PURPOSE: The association hepatocyte growth factor receptor (Met) tyrosine kinase with prognosis and survival in colon cancer is unclear, due in part to the limitation of detection methods used.
  • EXPERIMENTAL DESIGN: Fluorescent-based IHC for Met was done in 583 colon cancer patients in a tissue microarray format.
  • RESULTS: In crossvalidated and univariate Cox analysis, the membrane relative to cytoplasm Met score was a significant predictor of survival in stage I (hazard ratio, 0.16; P = 0.006) and in stage II patients (hazard ratio, 0.34; P < or = 0.0005).
  • Met in the membrane alone was not a significant predictor of outcome in all patients or within stage.
  • CONCLUSIONS: These data indicate that the relative subcellular distribution of Met, as measured by novel automated image analysis, may be a valuable biomarker for estimating colon cancer prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Cell Membrane / metabolism. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Cytoplasm / metabolism. Proto-Oncogene Proteins / metabolism. Receptors, Growth Factor / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559601.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Receptors, Growth Factor; EC 2.7.10.1 / MET protein, human; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


24. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol; 2010 Jan 20;28(3):466-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
  • We took advantage of PETACC-3, an adjuvant trial with 3,278 patients with stage II to III colon cancer, to evaluate the prognostic value of KRAS and BRAF tumor mutation status in this setting.
  • RESULTS: KRAS and BRAF tumor mutation rates were 37.0% and 7.9%, respectively, and were not significantly different according to tumor stage.
  • In a multivariate analysis containing stage, tumor site, nodal status, sex, age, grade, and microsatellite instability (MSI) status, KRAS mutation was associated with grade (P = .0016), while BRAF mutation was significantly associated with female sex (P = .017), and highly significantly associated with right-sided tumors, older age, high grade, and MSI-high tumors (all P < 10(-4)).
  • CONCLUSION: In stage II-III colon cancer, the KRAS mutation status does not have major prognostic value.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics. ras Proteins / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20008640.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


25. Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, Podhorny N, Bjerkeset O, Eide TJ, Halvorsen TB, Tveit KM, Norwegian Gastrointestinal Cancer Group: Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol; 2009;48(3):368-76
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
  • BACKGROUND: The recommendation of adjuvant chemotherapy for colon cancer with lymph node metastases, based on two studies from USA, was reluctantly accepted by Norwegian medical doctors.
  • MATERIAL AND METHODS: Four hundred and twenty five patients with operable colon and rectum cancer, Stage II and III (Dukes' stage B and C), were from January 1993 to October 1996, included in a randomised multicentre trial in Norway.
  • There was no difference between the two groups when analysed for colon and rectum separately.
  • However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs. 37% (p=0.012) and CSS, 65% vs. 47% (p=0.032) in favour of adjuvant chemotherapy.
  • CONCLUSIONS: Colon cancer patients with lymph node metastases benefit from adjuvant chemotherapy with 5-FU/Lev with acceptable toxicity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Antirheumatic Agents / therapeutic use. Colonic Neoplasms / drug therapy. Fluorouracil / therapeutic use. Levamisole / therapeutic use. Rectal Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19242829.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antirheumatic Agents; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Song W, He YL, Cai SR, Zhang CH, Chen CQ, Peng JJ, Zhan WH: [Clinical features of colorectal mucinous adenocarcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Sep;12(5):487-90
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of colorectal mucinous adenocarcinoma].
  • OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma (MAC) and non-mucinous adenocarcinoma (NMAC).
  • METHODS: Clinical data of 2089 cases with colorectal cancer from 1994 to 2007 in our hospital, including 169 patients diagnosed as mucinous adenocarcinoma were analyzed retrospectively.
  • The rates of tumor location in colon (97 cases,57.4% vs 814 cases, 44.3%, in MAC and NMAC) were significantly different (P<0.01).
  • The rate of radical resection (86.4% vs 91.5%), hepatic metastasis (5.3% vs 8.5%) and local recurrence had no significant difference between patients with mucinous and non-mucinous adenocarcinoma (P>0.05).
  • In comparison to NMAC patients, MAC patients were worse in long-term overall survival, the survival of receiving radical resection and of TNM stage (II+III) group (P<0.01).
  • Survivals were not significantly different in TNM stage I and IV groups between mucinous and non-mucinous adenocarcinoma (P>0.05).
  • CONCLUSIONS: Colorectal mucinous adenocarcinoma patients have worse outcome in comparison to non-mucinous adenocarcinoma patients.
  • Mucinous adenocarcinoma may have special biological behavior, which is an independent prognostic factor for patients with colorectal cancer.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19742341.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N: Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. Cancer; 2007 Nov 1;110(9):1945-50
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
  • BACKGROUND: Cases of severe gastrointestinal toxicity were monitored prospectively during NSABP C-07, a randomized clinical trial of adjuvant therapy for patients with stage II/III colon cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colonic Diseases / chemically induced. Colonic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17853393.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00004931
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-12027; United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69651; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


28. Jang KS, Song YS, Jang SH, Min KW, Na W, Jang SM, Jun YJ, Lee KH, Choi D, Paik SS: Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology; 2010 Jan;56(2):229-39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma.
  • On univariate survival analysis, patients with PTEN- adenocarcinoma revealed a poor overall and disease-free survival (P = 0.030 and P = 0.046, respectively).
  • On multivariate analysis, a significant difference was observed in patients with stage II cancer that was not observed in other stages.
  • CONCLUSIONS: Nuclear PTEN expression gradually decrease during the normal-adenoma-adenocarcinoma-metastasis sequence, which suggests an important role for PTEN in carcinogenesis.
  • Moreover, loss of nuclear PTEN expression was a marker of poor clinical outcome in patients with stage II colorectal cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenomatous Polyps / metabolism. Cell Nucleus / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Lymph Nodes / metabolism. PTEN Phosphohydrolase / metabolism. Rectum / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20102402.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


29. Wick MR, Vitsky JL, Ritter JH, Swanson PE, Mills SE: Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma. Am J Clin Pathol; 2005 Jan;123(1):56-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic medullary carcinoma of the colon: a clinicopathologic comparison with nonhereditary poorly differentiated enteric-type adenocarcinoma and neuroendocrine colorectal carcinoma.
  • We studied 68 sporadic colorectal carcinomas (CRCs) with medullary features (MCRCs) and compared them with 35 poorly differentiated purely "enteric" CRCs (ECRCs) and 15 purely neuroendocrine carcinomas (NECs) of grades II and III, all in patients lacking a family history of CRC.
  • MCRCs were significantly more common in the ascending colon than were ECRCs, but there was no significant dissimilarity to NECs.
  • Despite an infiltrative growth pattern, MCRC was less likely than ECRC to manifest with stage III or IV disease, but there was no stage-related difference from NECs.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Medullary / pathology. Carcinoma, Neuroendocrine / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762280.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Schetter AJ, Nguyen GH, Bowman ED, Mathé EA, Yuen ST, Hawkes JE, Croce CM, Leung SY, Harris CC: Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res; 2009 Sep 15;15(18):5878-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma.
  • PURPOSE: Inflammatory genes and microRNAs have roles in colon carcinogenesis; therefore, they may provide useful biomarkers for colon cancer.
  • This study examines the potential clinical utility of an inflammatory gene expression signature as a prognostic biomarker for colon cancer in addition to previously examined miR-21 expression.
  • EXPERIMENTAL DESIGN: Quantitative reverse transcriptase-PCR. was used to measure the expression of 23 inflammatory genes in colon adenocarcinomas and adjacent noncancerous tissues from 196 patients.
  • This association was strong for stage II cases (P = 0.002).
  • Both IRS and miR-21 expression were independently associated with cancer-specific mortality, including stage II patients alone.
  • CONCLUSION: IRS and miR-21 expression are independent predictors of colon cancer prognosis and may provide a clinically useful tool to identify high-risk patients.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Apr 1;101(7):2620-7 [12411307.001]
  • [Cites] Med Oncol. 2009;26 Suppl 1:13-7 [19148594.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Lancet. 1987 Jun 6;1(8545):1303-6 [2884421.001]
  • [Cites] Lancet. 1990 Aug 11;336(8711):357-9 [1975343.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] Int J Cancer. 1999 Jun 21;84(3):326-30 [10371355.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3698-704 [10446984.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] J Immunol. 2005 Nov 1;175(9):6177-89 [16237115.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Immunity. 2000 Nov;13(5):715-25 [11114383.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1035-44 [12016129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):143-8 [12518062.001]
  • [Cites] Nat Rev Immunol. 2003 Feb;3(2):133-46 [12563297.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Cancer Cell. 2006 Aug;10(2):99-111 [16904609.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Cancer Biother Radiopharm. 2006 Oct;21(5):468-87 [17105420.001]
  • [Cites] Annu Rev Med. 2007;58:239-52 [17100552.001]
  • [Cites] Eur J Cancer. 2007 Mar;43(4):762-8 [17258448.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1175-83 [17476347.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1330-3 [17496199.001]
  • [Cites] BMC Genomics. 2007;8:240 [17640343.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1257-69 [17686824.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2373-80 [17893866.001]
  • [Cites] PLoS One. 2007;2(10):e1020 [17925868.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D149-53 [18158296.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):11-8 [18066650.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] Lancet. 2008 Mar 1;371(9614):771-83 [18275997.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):595-604 [18402526.001]
  • [Cites] J Mol Biol. 2008 May 2;378(3):492-504 [18384814.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1296-310 [18471507.001]
  • [Cites] Gut. 2008 Jun;57(6):772-9 [17965063.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2664-5 [18565858.001]
  • [Cites] Carcinogenesis. 2008 Jun;29(6):1202-6 [18448485.001]
  • [Cites] Immunol Rev. 2008 Jun;223:114-31 [18613832.001]
  • [Cites] Ann Oncol. 2008 Oct;19(10):1734-41 [18550579.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6735-41 [18980965.001]
  • [Cites] Genome Res. 2009 Jan;19(1):92-105 [18955434.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):600-7 [12847224.001]
  • (PMID = 19737943.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999; United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / MIRN21 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ NIHMS125003; NLM/ PMC2745503
  •  go-up   go-down


31. Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, Parfrey P, Gallinger S, Pollett WG: Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. Can J Surg; 2009 Apr;52(2):92-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces.
  • The American Society of Clinical Oncology and Cancer Care Ontario have recommended adjuvant chemotherapy for patients with high-risk stage II colon cancer.
  • We evaluated differences in concordance with guidelines in the treatment of patients with stage I-III colon cancer in the Canadian provinces of Newfoundland and Labrador and Ontario.
  • METHODS: We assessed clinical data and treatment from January 1999 to December 2000 for 130 patients from Newfoundland and Labrador and 315 patients from Ontario who had stage I-III colon cancer.
  • We evaluated factors affecting the use of chemotherapy in patients with stage II disease.
  • RESULTS: No patients received adjuvant therapy for stage I disease.
  • Forty-five of 52 patients (87%) in Newfoundland and Labrador and 108 of 115 patients (94%) in Ontario received adjuvant chemotherapy for stage III colon cancer.
  • Twenty of 55 patients (36%) in Newfoundland and Labrador and 44 of 116 patients (38%) in Ontario received adjuvant therapy for stage II disease.
  • There was a strong trend toward using chemotherapy in patients with stage II disease who were 50 years or younger, independent of high-risk status.
  • CONCLUSION: Concordance with CPGs for adjuvant chemotherapy in patients with stage II colon cancer was not optimal.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Age Factors. Aged. Humans. Middle Aged. Multivariate Analysis. Newfoundland and Labrador. Ontario. Patient Selection. Registries. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 Oct 20;282(15):1458-65 [10535437.001]
  • [Cites] Am J Gastroenterol. 2006 Jun;101(6):1320-8 [16771956.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Chronic Dis Can. 2000;21(2):81-6 [11007659.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Intern Med J. 2004 Aug;34(8):492-500 [15317548.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] CMAJ. 1993 Feb 15;148(4):507-12 [8431814.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):502-12 [7844612.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1369-72 [7577053.001]
  • [Cites] Nat Med. 1995 Apr;1(4):348-52 [7585065.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Med Care Res Rev. 2004 Dec;61(4):453-73 [15536209.001]
  • [Cites] Health Aff (Millwood). 2005 Jan-Feb;24(1):18-28 [15647212.001]
  • [Cites] Cancer. 2005 Apr 25;105(2):101-9 [15643601.001]
  • [Cites] Eval Health Prof. 2006 Mar;29(1):65-88 [16510880.001]
  • [Cites] Qual Health Care. 1999 Sep;8(3):177-83 [10847875.001]
  • (PMID = 19399202.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2663496
  •  go-up   go-down


32. Yamamoto S, Yoshimura K, Konishi F, Watanabe M: Phase II trial to evaluate laparoscopic surgery for Stage 0/I rectal carcinoma. Jpn J Clin Oncol; 2008 Jul;38(7):497-500
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial to evaluate laparoscopic surgery for Stage 0/I rectal carcinoma.
  • Recently reported randomized controlled trials demonstrated that laparoscopic surgery (LS) was comparable or superior to open surgery with regard to the long-term outcome for colon and rectosigmoidal carcinoma; however, controversy persists with regard to the appropriateness of LS for patients with rectal carcinoma.
  • To examine the technical and oncological feasibility of LS for rectal carcinoma, a phase II trial was started in patients with a preoperative diagnosis of Stage 0/I rectal carcinoma, under the direction of the Japan Society of Laparoscopic Colorectal Surgery.
  • The primary end-point in the first stage is the anastomotic leakage rate by double-stapling technique and that in the second stage is overall survival.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586667.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


33. Arfa N, Hamdani I, Gharbi L, Ben Abid S, Ghariani B, Mannai S, Mestiri H, Khalfallah MT, Mzabi SR: [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases]. Ann Chir; 2006 Feb;131(2):104-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival and prognostic factors of colorectal adenocarcinoma: analytic multifactor review of 150 cases].
  • [Transliterated title] Survie et facteurs pronostiques des adénocarcinomes colorectaux: étude analytique uni- et multifactorielle de 150 cas.
  • This study attempts to observe the survival of colorectal adenocarcinoma and to find prognostic factors and other variables potentially associated with outcome of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: It's a retrospective study based on 150 patients with colorectal adenocarcinoma from 1990 to 2002.
  • 84 patients had colon adenocarcinoma and 66 patients had rectal adenocarcinoma.
  • In histological exam the adenocarcinoma was well differenced in 69 cases (46%), and undifferentiated in 17 cases (18, 3%).
  • There were 6 patients (4%) Dukes stage I TNM, 61 stage II (40, 7%), 51 stage III TNM (34%) and 32 patients stage IV TNM (34%).
  • All patients had surgical curative resection associated with adjuvant chemotherapy in 60 cases of colon adenocarcinoma and preoperative radiotherapy in 33 cases of rectal adenocarcinoma.
  • In addition to the clinical factors, we found of significant prognostic value undifferentiated adenocarcinoma and an elevated value of serum carcinoembryonic antigen>5 ng/ml.
  • [MeSH-major] Adenocarcinoma / mortality. Colorectal Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16443189.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. Dahl O: [Adjuvant chemotherapy for colon cancer]. Tidsskr Nor Laegeforen; 2007 Nov 29;127(23):3094-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy for colon cancer].
  • BACKGROUND: Radical resection is the main treatment for adenocarcinoma of the colon.
  • The background for adjuvant chemotherapy of colon cancer is presented.
  • RESULTS AND INTERPRETATION: Cure rates after curative resections of colon cancer (stage III) are improved by about 12% if patients are treated with adjuvant chemotherapy with oxaliplatin combined with 5-fluoruracil and folinat (or capecitabine) for 6 months.
  • Certain subgroups of stage II (Dukes' stage B) are also likely to benefit from adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18049502.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


35. Sprenger T, Rothe H, Jung K, Christiansen H, Conradi LC, Ghadimi BM, Becker H, Liersch T: Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol; 2010;8:27
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
  • METHODS: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied.
  • Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Clinical Trials, Phase II as Topic. Clinical Trials, Phase III as Topic. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Preoperative Care. Prospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):110-7 [17194912.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2573-9 [17577036.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4379-86 [17906203.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6617-23 [18006762.001]
  • [Cites] Dis Colon Rectum. 2008 Mar;51(3):277-83 [18183463.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):57-64 [18442099.001]
  • [Cites] J Surg Oncol. 2009 Dec 1;100(7):525-8 [19697351.001]
  • [Cites] Cancer. 2009 Dec 1;115(23):5432-40 [19673001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1158-65 [19800178.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):157-63 [11134208.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Arch Surg. 2002 Feb;137(2):206-10 [11822961.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1729-34 [11919228.001]
  • [Cites] ANZ J Surg. 2002 Jul;72(7):483-7 [12123507.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):895-903 [12130878.001]
  • [Cites] Semin Surg Oncol. 2003;21(1):19-22 [12923912.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Br J Surg. 1982 Oct;69(10):613-6 [6751457.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Z Gastroenterol. 2008 Aug;46(8):799-840 [18759205.001]
  • [Cites] Ann Surg. 2009 Jun;249(6):965-72 [19474683.001]
  • [Cites] J Surg Oncol. 2009 Oct 1;100(5):387-91 [19582821.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Colorectal Dis. 1997;12(1):19-23 [9112145.001]
  • [Cites] N Engl J Med. 1997 Jul 31;337(5):346-7; author reply 347-8 [9235500.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Dec 1;42(5):935-41 [9869213.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):167-73 [10211491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):426-31 [15667963.001]
  • [Cites] Cancer. 2005 Feb 1;103(3):647-9 [15612025.001]
  • [Cites] Surg Today. 2005;35(6):442-5 [15912290.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8688-96 [16246976.001]
  • [Cites] Ann Surg. 2006 Apr;243(4):492-8 [16552200.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1284-92 [16758130.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4620-5 [17008704.001]
  • (PMID = 20388220.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2864265
  •  go-up   go-down


36. Gertler R, Rosenberg R, Schuster T, Friess H: Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy. Eur J Cancer; 2009 Nov;45(17):2992-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining a high-risk subgroup with colon cancer stages I and II for possible adjuvant therapy.
  • AIM: Adjuvant therapy is not routinely recommended in UICC stages I and II colon cancer, but may be considered for high-risk patients.
  • Our aim is to identify clinicopathologic characteristics in colon cancer stages I and II, which are associated with an increased risk of tumour recurrence and tumour-related death.
  • METHODS: We analysed our prospectively documented clinical database of 775 patients with colon cancer stages I and II, which underwent curative resection between 1982 and 2006.
  • CONCLUSION: Patients with stage I or II colon cancer have a favourable prognosis after radical resection.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682890.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


37. Bellone G, Gramigni C, Vizio B, Mauri FA, Prati A, Solerio D, Dughera L, Ruffini E, Gasparri G, Camandona M: Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa. Int J Oncol; 2010 Nov;37(5):1153-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa.
  • The simultaneous expression of Endoglin (CD105), transforming growth factor (TGF)-β1 and TGF-β receptor (R) II were quantified in surgical specimens comprising normal human colon, pre-malignant dysplastic tissue, in situ, and invasive colon cancer specimens, at mRNA and protein levels, respectively by real-time PCR and immunohistochemistry.
  • Serum concentrations of soluble Endoglin and TGF-β1 were evaluated. mRNA and CD105+-microvessel density (MVD) increased significantly in dysplastic colon and carcinoma versus normal tissues; values correlated respectively with dysplasia degree and Dukes' stages.
  • TGF-β1 RII was overexpressed in adenoma and carcinoma versus normal samples, but unrelated with dysplasia or Dukes' stage.
  • These findings suggest active angiogenesis occurs in many pre-malignant colon cases and supports more careful evaluation of different chemopreventive agents.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD / biosynthesis. Colonic Neoplasms / metabolism. Precancerous Conditions / metabolism. Protein-Serine-Threonine Kinases / biosynthesis. Receptors, Cell Surface / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis. Transforming Growth Factor beta1 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878063.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


38. Shaikh AJ, Raza S, Shaikh AA, Idress R, Kumar S, Rasheed YA, Lal A, Masood N: Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan. Asian Pac J Cancer Prev; 2009 Jul-Sep;10(3):361-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demographics, pathologic patterns and long-term survival in operable colon cancers: local experience in Pakistan.
  • BACKGROUND: Colon cancer is a common malignancy with its incidence reportedly rising in Asian countries, including Pakistan.
  • There are no comprehensive data available from Pakistan which focus on associations of various factors with long-term survival of colon cancer.
  • METHODOLOGY: In this retrospective study adult patients with colon cancer diagnosed through 2000-2003 were included.
  • Of the total, 49.5% of the patients had right sided (mortality rate 51.6%), 10.8% had transverse colon, (mortality rate 37.5%), 7.5% had descending colon (mortality rate 66.7%) and 32.2% had sigmoid colon (mortality rate 40.9%) cancers.
  • Stage I disease on diagnosis was found in 16%, stage II in 42.7 (mortality 40 %) and stage III in 41.3% (mortality 70 %).
  • Most patients had pure adenocarcinoma while a mucinous type differentiation was seen in 19.7%, 3% had signet ring morphology, 1.5% adeno-squamous carcinoma and similar number with neuroendocrine differentiation.
  • CONCLUSION: Colon cancer in Pakistan commonly presents at an advanced stage, there is a male preponderance, and relatively mean younger age at presentation for males is seen.
  • Advanced stage and lymph node involvement along with poorly differentiated pathology, signet ring or mucinous morphology, location in descending colon, positive surgical margins and removal of less than twelve lymph nodes are factors associated with poor long term survival.
  • There is a need to reinforce information about colon cancer and larger studies from the region are needed to confirm the factors analyzed here.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Colonic Neoplasms / mortality. Colonic Neoplasms / pathology. Neoplasm Recurrence, Local / mortality. Survivors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19640173.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


39. Snaebjörnsson P, Jónasson L, Jónsson T, Möller PH, Theodórs A, Jónasson JG: [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference]. Laeknabladid; 2009 Jun;95(6):423-30

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon cancer in Iceland 1955-2004. Study on epidemiology, histopathology and gender difference].
  • OBJECTIVE: Colon cancer is the third most common cancer in Iceland.
  • The aim of this study was to analyze the epidemiology and histopathology of colon cancer in Iceland, resection rate and the difference between men and women.
  • MATERIAL AND METHODS: Pathology and autopsy reports for all patients diagnosed with colon cancer between 1955 and 2004 where reviewed.
  • Most tumors were located in the sigmoid colon (35%).
  • Adenocarcinomas where 84% and mucinous adenocarcinoma 7%.
  • Altogether 7% of cases were TNM-stage I, 32% were stage II, 24% stage III, 21% in stage IV and stage was unknown in 16% of cases.
  • CONCLUSION: Incidence of colon cancer increased considerably, mainly for men.
  • Surgical rate and pathology of colon cancer is similar to that reported elsewhere except that there are somewhat fewer cases in TNM-stage I.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma, Mucinous / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Laeknabladid. 2009 Jun;95(6):419 [19491405.001]
  • (PMID = 19491407.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


40. Ianoşi G, Mercuţ D, Neagoe D, Ianoşi S, Drighiciu C, Resceanu A, Andriţoiu A, Manolache A: Histopathological factors as predictors for survival in colon and rectal cancers. Rom J Morphol Embryol; 2008;49(3):365-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological factors as predictors for survival in colon and rectal cancers.
  • We included in our study 273 patients with colon and rectal cancers admitted in Surgical Clinic of Military Hospital of Craiova in which we evaluate the clinical-pathological features, location of the distant metastasis, postoperative staging, curability and survival.
  • We established correlations, inside of a same stage of the disease, for pathological features (characters of the tumors, differentiation grade and location) and survival rate.
  • Tumor differentiation is correlated with survival only for the patients with stage II and III of the disease, perineural invasion and pathologic N stage representing important predicting factors for a shorter survival.
  • Peritoneal washing for cytology prior to surgery is correlated with the stage of the disease and not with tumor differentiation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758642.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


41. Harder J, Engelstaedter V, Usadel H, Lassmann S, Werner M, Baier P, Otto F, Varbanova M, Schaeffner E, Olschewski M, Blum HE, Opitz OG: CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer; 2009 Jan 27;100(2):360-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients.
  • Patients with UICC stage II colorectal cancer (CRC) have a risk of approximately 20% to develop disease recurrence after tumour resection.
  • Therefore, we evaluated the methylation status of the ER promoter in lymph nodes from 49 patients with CRC UICC stage I and II as a molecular marker of micrometastases and predictor of local recurrence.
  • The methylation status of the ER promoter in lymph nodes of UICC stage I and II CRC patients may be a useful marker for the identification of patients at a high risk for local recurrence.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Colon / metabolism. Colon / pathology. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rectum / metabolism. Rectum / pathology. Reverse Transcriptase Polymerase Chain Reaction. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1996 Feb 15;56(4):722-7 [8631003.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):973-77 [8640788.001]
  • [Cites] Lab Invest. 1997 Dec;77(6):685-95 [9426407.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Clin Exp Metastasis. 1998 Jan;16(1):3-8 [9502072.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1227-34 [9607581.001]
  • [Cites] J Surg Oncol. 1998 May;68(1):34-40 [9610661.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2515-9 [9635570.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):505-14 [9641495.001]
  • [Cites] N Engl J Med. 1998 Jul 23;339(4):223-8 [9673300.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2632-40 [9704713.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2450-4 [10499618.001]
  • [Cites] J Surg Oncol. 2006 Jan 1;93(1):13-8; discussion 18-9 [16353185.001]
  • [Cites] J Pathol. 2006 Mar;208(4):462-72 [16402339.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):218-25 [16755296.001]
  • [Cites] Hum Pathol. 2006 Oct;37(10):1259-67 [16949928.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):167-73 [16721490.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):767-72 [17228023.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2327-35 [18467724.001]
  • [Cites] Br J Cancer. 1999 Nov;81(5):870-3 [10555760.001]
  • [Cites] Ann Intern Med. 1999 Dec 7;131(11):805-12 [10610624.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Cancer Detect Prev. 2000;24(1):72-9 [10757125.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1350-7 [11350905.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1049-55 [11844829.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):759-67 [11895906.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4232-41 [12377967.001]
  • [Cites] Dis Colon Rectum. 2003 Feb;46(2):221-31 [12576896.001]
  • [Cites] Scand J Gastroenterol. 2003 Feb;38(2):125-32 [12678327.001]
  • [Cites] Int J Surg Investig. 2000;2(1):49-57 [12774338.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):87-94 [13680284.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4444-9 [15240535.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5777-84 [15355906.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • (PMID = 19142184.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC2634714
  •  go-up   go-down


42. Törnroos A, Garvin S, Olsson H: The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer. Acta Oncol; 2009;48(8):1152-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The number of identified lymph node metastases increases continuously with increased total lymph node recovery in pT3 colon cancer.
  • BACKGROUND. The positive correlation between the number of recovered benign lymph nodes and patient prognosis is well established for stage II colon cancer patients.
  • One theory explaining this correlation focuses on potential understaging of cancer specimen, implying that a specimen with few examined lymph nodes is likely to be assigned a lower N-stage than the correct one.
  • This study aims to investigate the association between the total lymph node harvest and the number of lymph node metastases in colon cancer specimen.
  • We studied the original pathology reports of 649 patients diagnosed with T3 adenocarcinoma of the colon at the Department of Clinical Pathology and Genetics at Linköping University Hospital, Linköping, Sweden between the years 2000 and 2008.
  • Rather than focusing on a recommended minimum number of nodes, efforts should be shifted towards developing methods assuring that colon cancer specimen are dissected in a standardized way that optimizes the lymph node harvest.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19863223.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Mammen JM, James LE, Molloy M, Williams A, Wray CJ, Sussman JJ: The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry. Am J Surg; 2007 Sep;194(3):349-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of lymph node dissection and colon cancer survival in the Veterans Affairs Central Cancer Registry.
  • BACKGROUND: The extent of lymphadenectomy in colon cancer may impact potential to cure and accuracy of staging.
  • METHODS: The Veterans Affairs Central Cancer Registry database was queried for TNM stage I-III colon adenocarcinoma patients and yielded 5,823 individuals.
  • RESULTS: The overall survival (OS) in stage II patients was greater with the higher number of lymph node (LN) examined.
  • For stage II patients, the 5-year OS was 34%, 43%, 47%, and 55% for the lowest to highest quartiles (P = .007).
  • For stage III patients, the 5-year OS was 31%, 27%, 38%, and 53% for the lowest to highest quartiles (not significant overall).
  • CONCLUSIONS: More extensive lymphadenectomy is associated with improved OS in stage II colon cancer patients.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colonic Neoplasms / mortality. Colonic Neoplasms / surgery. Lymph Node Excision

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693281.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD: Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst; 2005 Aug 3;97(15):1124-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.
  • METHODS: We applied methylation-specific polymerase chain reaction to the vimentin gene, which is transcriptionally silent in normal colonocytes, and compared methylation of vimentin exon 1 in cancer tissues and in fecal DNA from colon cancer patients versus control samples from healthy subjects.
  • RESULTS: Vimentin exon-1 sequences were unmethylated in 45 of 46 normal colon tissues.
  • In contrast, vimentin exon-1 sequences were methylated in 83% (38 of 46) and 53% (57 of 107) of tumors from two independently collected groups of colon cancer patients.
  • When evaluated as a marker for colon cancer detection in fecal DNA from another set of colon cancer patients, aberrant vimentin methylation was detected in fecal DNA from 43 of 94 patients, for a sensitivity of 46% (95% confidence interval [CI] = 35% to 56%).
  • The sensitivity for detecting stage I and II cancers was 43% (26 of 60 case patients) (95% CI = 31% to 57%).
  • CONCLUSIONS: Aberrant methylation of exon-1 sequences within the nontranscribed vimentin gene is a novel molecular biomarker of colon cancer and can be successfully detected in fecal DNA to identify nearly half of individuals with colon cancer.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenoma / diagnosis. Adenoma / genetics. Case-Control Studies. Cell Transformation, Neoplastic. Humans. Occult Blood. Polymerase Chain Reaction. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Cancer Inst. 2005 Aug 3;97(15):1107-9 [16077063.001]
  • (PMID = 16077070.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA43703; United States / NCI NIH HHS / CA / R01 CA66725; United States / NCI NIH HHS / CA / R01 CA67409; United States / NCI NIH HHS / CA / R25T CA094186
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Vimentin
  •  go-up   go-down


45. Jestin P, Påhlman L, Glimelius B, Gunnarsson U: Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination. Eur J Cancer; 2005 Sep;41(14):2071-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer staging and survival in colon cancer is dependent on the quality of the pathologists' specimen examination.
  • Correct staging of colon cancer is decisive regarding further oncological treatment, surveillance and prediction of long-term survival.
  • Data from the colon cancer register (1997-2002) of the Uppsala/Orebro, Sweden, health care region were analysed and the seven pathology departments in this region were compared.
  • Included were 3735 patients who had undergone resection of a colon cancer.
  • Survival in stage II was lower when fewer than 12 nodes were examined or when the number of nodes sampled was not given (P = 0.001, log-rank test).
  • In stage III, those with at the most 3 nodes positive (N1) had a better survival than those with 4 or more nodes positive (N2) (P < 0.001, log-rank test).
  • An index of metastases (IM), derived from the number of nodes with metastases divided by the number of nodes examined, was calculated for stage III tumours.
  • Examination of 12 nodes is necessary to assure stage III cases with the median IM (0.32), whereas 20 nodes are necessary to assure 90% of cases with the lower quartile of IM (0.16).
  • The prognostic information of the IM was higher than that of the N-stage.
  • An index of metastases (IM) is a possible basis for guidance in the choice of adjuvant treatments that appears superior to that of N-stage.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125926.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


46. Sinicrope FA, Rego RL, Foster N, Sargent DJ, Windschitl HE, Burgart LJ, Witzig TE, Thibodeau SN: Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers. Am J Gastroenterol; 2006 Dec;101(12):2818-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers.
  • OBJECTIVE: Colon cancers with high frequency microsatellite instability (MSI-H) are preferentially located in the proximal colon.
  • Given that 15-20% of sporadic colon cancers are MSI-H, we determined whether tumor site-specific differences in clinicopathological variables, biomarkers, and prognosis are due to inclusion of MSI-H cases.
  • METHODS: TNM stage II and III primary colon carcinomas (N = 528) from patients enrolled in 5-fluorouracil-based adjuvant trials were analyzed for MSI using 11 microsatellite markers.
  • RESULTS: MSI-H was found in 95 (18%) colon cancers.
  • CONCLUSIONS: Tumor site-related differences in clinicopathological variables, biomarkers, and prognosis of sporadic colon cancers can be explained by the inclusion of MSI-H cases.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17026563.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA074800; United States / NCI NIH HHS / CA / CA 104683
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


47. Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS, Catalano PJ, Haller DG: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol; 2005 Dec 1;23(34):8706-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes.
  • PATIENTS AND METHODS: We analyzed data from Intergroup trial 0089 of adjuvant chemotherapy for stage II and III patients with colon cancer, in which all patients received fluorouracil-based therapy.
  • Covariates included in the models were age, sex, tumor stage, grade, histology, number of positive LNs, number of LNs removed, and LNR.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / therapy. Lymphatic Metastasis / pathology

  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314630.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Fazeli MS, Adel MG, Lebaschi AH: Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University. Dis Colon Rectum; 2007 Jul;50(7):990-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma: a retrospective, descriptive study of age, gender, subsite, stage, and differentiation in Iran from 1995 to 2001 as observed in Tehran University.
  • These factors also are evaluated in conjunction with disease stage and tumor differentiation at the time of diagnosis.
  • METHODS: Data from 419 patients from a population that receives no screening between April 1995 and March 2001 operated on in the Cancer Institute and Imam Khomieni Hospital with a diagnosis of colorectal cancer were used to describe distribution of the colorectal carcinoma by age, gender, tumor subsite and pathology, and stage at diagnosis.
  • RESULTS: There were 403 (96.2 percent) cases of adenocarcinoma.
  • Patients were divided into two age groups (40 years and younger, and older than 40 years); 16.4 percent of patients had tumors in the proximal colon and 83.6 percent in distal parts.
  • Most patients were Stage II and III (48.1 and 33.4 percent, respectively).
  • Most patients in the younger age group were Stage III (45 percent) and in the older age group were Stage II (53.2 percent; P<0.001).
  • There were no differences in stage and tumor differentiation between two genders, but most of the patients with tumors in proximal colon were males (62.5 percent; P=0.1).
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525859.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Barrier A, Lemoine A, Boelle PY, Tse C, Brault D, Chiappini F, Breittschneider J, Lacaine F, Houry S, Huguier M, Van der Laan MJ, Speed T, Debuire B, Flahault A, Dudoit S: Colon cancer prognosis prediction by gene expression profiling. Oncogene; 2005 Sep 8;24(40):6155-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer prognosis prediction by gene expression profiling.
  • This study assessed the possibility to build a prognosis predictor, based on microarray gene expression measures, in stage II and III colon cancer patients.
  • This study suggests that one can build an accurate prognosis predictor for stage II and III colon cancer patients, based on gene expression measures, and one can use either tumour or non-neoplastic mucosa for this purpose.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Gene Expression Profiling. Genetic Markers. Oligonucleotide Array Sequence Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16091735.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


50. Dugalic V, Gojnic M, Brankovic M, Stojanovic I, Ser F, Zizic V: Bone metastasis arising from a polyp of the cervix as the first symptom in generalized multi-organ adenocarcinoma. Eur J Gynaecol Oncol; 2010;31(5):593-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone metastasis arising from a polyp of the cervix as the first symptom in generalized multi-organ adenocarcinoma.
  • During Werthaim-Meigs surgery, four positive glandules and cervical adenocarcinoma Stage II were found.
  • The colon was removed, as a right hemicolectomy, as well as the iliac bone upper segment.
  • Unfortunately, considering the changes in the tissue of the colon and cervix, we considered the condition to be "generalized" adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology


51. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.
  • These results suggest a rationale for the use of SirT1 activators and inhibitors in the prevention and treatment of colon cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


52. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA: Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer; 2010 Jan 5;102(1):165-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.
  • BACKGROUND: Evidence suggests that epidermal growth factor receptor (EGFR)-activation status may better predict the clinical behaviour of colon cancers than does EGFR expression.
  • However, the prognostic effect of phospho-EGFR in primary colon cancer remains undefined.
  • METHODS: Phospho-EGFR (Tyr-1173) and EGFR expression were analysed by immunohistochemistry (IHC) in tissue microarrays of TNM stage II and III colon cancers from completed adjuvant therapy trials (n=388).
  • Although phospho-EGFR was unrelated to clinicopathological variables, strong EGFR intensity was associated with higher tumour stage (P=0.03).
  • Stage and lymph node number were prognostic for DFS and OS, and histological grade for OS.
  • EGFR was an independent predictor of DFS (P=0.042) after adjustment for stage, histological grade, age, and MMR status.

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(21):7875-86 [14560030.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6487-501 [15475436.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] J Biol Chem. 1994 Jul 15;269(28):18674-8 [8034616.001]
  • [Cites] Eur J Surg Oncol. 1995 Jun;21(3):269-75 [7781795.001]
  • [Cites] Biochemistry. 1995 Dec 19;34(50):16456-66 [8845374.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26091-7 [10473558.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):1803-10 [15677699.001]
  • [Cites] Int J Oncol. 2005 Aug;27(2):317-25 [16010411.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1350-6 [15832190.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S59-62 [16399434.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1169-77 [16505437.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2834-43 [16510606.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Br J Cancer. 2006 Dec 4;95(11):1525-8 [17088913.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Lung Cancer. 2007 Mar;55(3):349-55 [17161498.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2184-90 [17538163.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3597-604 [17575224.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4405-13 [17906204.001]
  • [Cites] Ann Oncol. 2008 Dec;19(12):2033-8 [18632722.001]
  • [Cites] Pathology. 2009;41(4):356-60 [19404848.001]
  • [Cites] Curr Opin Oncol. 2009 Jul;21(4):369-73 [19444104.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4531-7 [19584170.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):77-81 [10964085.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Eur J Cancer. 2002 May;38(8):1065-71 [12008194.001]
  • [Cites] Eur J Cancer. 2002 Nov;38(17):2258-64 [12441262.001]
  • [Cites] Eur J Cancer. 2003 Jul;39(10):1348-54 [12826036.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Virchows Arch. 2003 Aug;443(2):115-21 [12802583.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3069-75 [15131045.001]
  • (PMID = 19997103.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA 104683
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 21820-51-9 / Phosphotyrosine; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2813748
  •  go-up   go-down


53. Kim ST, Lee J, Park SH, Park JO, Lim HY, Kang WK, Kim JY, Kim YH, Chang DK, Rhee PL, Kim DS, Yun H, Cho YB, Kim HC, Yun SH, Lee WY, Chun HK, Park YS: Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol; 2010 Sep;66(4):659-67
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
  • PURPOSE: Colon cancer with DNA mismatch repair (MMR) defects reveals indistinguishable clinical and pathologic aspects, including better prognosis and reduced response to 5-fluorouracil (5-FU)-based chemotherapy.
  • This study investigated the clinical implication of MSI-H/MMR-D and p53 expression in R0-resected colon cancer patients who received adjuvant oxaliplatin/5-FU/leucovorin (FOLFOX) therapy.
  • EXPERIMENTAL DESIGN: We analyzed 135 patients, who had been treated by adjuvant chemotherapy containing 5-FU and oxaliplatin (FOLFOX) after curative resection (R0) for colon adenocarcinoma between May 2004 and November 2007.
  • RESULTS: There were 13 (9.6%) patients with stage II, 108 (80%) with stage III, and 14 (10.4%) with stage IV.
  • Fourteen patients with stage IV (10.3%) had metastases to liver only, all of whom underwent complete metastasectomy for liver metastases.
  • MMR status was not significantly associated with DFS (P = 0.56) or OS (P = 0.61) in patients with colon cancer (n = 135) receiving adjuvant FOLFOX.
  • CONCLUSION: The MMR status or p53 positivity was not significantly associated with outcomes to FOLFOX as adjuvant chemotherapy in colon cancer patients with R0 resection.
  • Adding oxaliplatin in adjuvant chemotherapy may overcome negative impact of 5-FU on colon cancers with MSI-H/MMR-D.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonic Neoplasms / drug therapy. Colonic Neoplasms / genetics. Microsatellite Instability / drug effects

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20033812.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / Organoplatinum Compounds; 0 / Tumor Suppressor Protein p53; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


54. Liang JT, Lai HS, Lee PH, Chang KJ: Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer. Ann Surg Oncol; 2008 Jun;15(6):1609-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pelvic autonomic nerve-preserving surgery for sigmoid colon cancer.
  • BACKGROUND: To test the feasibility of laparoscopic approach in performing the simultaneous pelvic autonomic nerve preservation during standard anterior resection of sigmoid colon cancer.
  • RESULTS: A total of 112 patients (tumor, node, metastasis system stage I, n = 8; stage II, n = 54; stage III, n = 50; male, n = 58; female, n = 54; age [mean +/- standard deviation], 55.8 +/- 6.4 years) with good baseline genitourinary function were operated on with the intent of total preservation of pelvic autonomic nerves and curative resection of sigmoid colon cancer.
  • CONCLUSIONS: Under laparoscopy, we can clearly identify and preserve the pelvic autonomic nerves to retain genitourinary function in most patients undergoing oncologic resection of sigmoid colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Autonomic Pathways / surgery. Colectomy. Sigmoid Neoplasms / surgery. Trauma, Nervous System / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2004 Apr;91(4):465-8 [15048749.001]
  • [Cites] Tech Coloproctol. 2003 Apr;7(1):29-33 [12750952.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2354-61 [16408331.001]
  • [Cites] Br J Surg. 2005 Nov;92(11):1444-8 [16184622.001]
  • [Cites] Br J Surg. 2005 Sep;92(9):1124-32 [15997446.001]
  • [Cites] Ann Surg. 2005 Aug;242(2):212-23 [16041212.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1178-85 [12352233.001]
  • [Cites] J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208 [10782451.001]
  • [Cites] Semin Surg Oncol. 2000 Apr-May;18(3):235-43 [10757889.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1354-7 [15362751.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):2206-14 [9951896.001]
  • [Cites] Ann Surg Oncol. 2007 Apr;14(4):1285-7 [17235719.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):109-17 [17066227.001]
  • [Cites] Int J Clin Oncol. 2006 Oct;11(5):339-43 [17058130.001]
  • [Cites] Dis Colon Rectum. 2004 Sep;47(9):1442-7 [15486739.001]
  • [Cites] Ann Surg. 1988 Oct;208(4):391-400 [3178328.001]
  • [Cites] Dis Colon Rectum. 1995 Nov;38(11):1162-8 [7587758.001]
  • [Cites] Cancer. 1996 Nov 1;78(9):1871-80 [8909305.001]
  • [Cites] Br J Surg. 1997 Apr;84(4):586-7 [9112939.001]
  • [Cites] Urology. 1997 Jun;49(6):822-30 [9187685.001]
  • [Cites] Br J Surg. 1998 Aug;85(8):1162 [9718031.001]
  • (PMID = 18365285.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2373867
  •  go-up   go-down


55. Scheiden R, Pescatore P, Wagener Y, Kieffer N, Capesius C: Colon cancer in Luxembourg: a national population-based data report, 1988-1998. BMC Cancer; 2005;5:52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon cancer in Luxembourg: a national population-based data report, 1988-1998.
  • BACKGROUND: Over the last two decades time trends in incidence rates of colorectal cancer, changes in the proportions of stage at diagnosis and changes in the anatomic sub-site distribution of colon cancers have been reported in some European countries.
  • In order to determine a strategy for early detection of colon cancer in the Grand-Duchy of Luxembourg, all consecutive colon adenocarcinomas diagnosed during the period 1988-1998 at a nation-wide level were reviewed.
  • METHODS: The population-based data of the national Morphologic Tumour Registry report all new high-grade adenomas (i.e. high-grade intraepithelial adenomatous neoplasias) and all consecutive new invasive adenocarcinomas of the colon diagnosed in the central department of pathology.
  • Attention has been focused on variations in incidence, stage, anatomical site distribution and survival rates.
  • RESULTS: Over the study period, 254 new colonic high-grade adenomas and 1379 new invasive adenocarcinomas were found; the crude incidence rates of colon adenocarcinomas grew steadily by 30%.
  • Comparing the two 5-year periods 1988-1992 and 1994-1998, the crude incidence rates of high-grade adenomas (stage 0) rose by 190%, that of stage I cases by 14.3%, stage II cases 12.9% and stage III cases 38.5%, whereas the crude incidence rates of stage IV cases decreased by 11.8%.
  • The high-grade adenoma/adenocarcinoma ratio increased.
  • The overall observed 5-year survival rate (stage I-IV) was 51 +/- 3% (95% confidence interval).
  • CONCLUSION: The increasing incidence rates of colon adenocarcinomas, the persistence of advanced tumour stages (stage III), the mortality rates which remain stable, and the changing trends in the age- and sub-site distribution underline the need for preventive measures at the age of 50 in asymptomatic patients to reduce mortality from colo(rectal) cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 2001 Dec 1;111(8):593-601 [11755501.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2547-54 [11745188.001]
  • [Cites] Oncologist. 2002;7(3):200-4 [12065791.001]
  • [Cites] Gut. 2002 Jul;51(1):60-4 [12077093.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Am Surg. 2002 Oct;68(10):871-6 [12412713.001]
  • [Cites] Eur J Cancer Prev. 2002 Dec;11(6):529-34 [12457104.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):544-60 [12557158.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jan;33(1):38-43 [12604723.001]
  • [Cites] Scand J Surg. 2003;92(1):5-9 [12705545.001]
  • [Cites] An Sist Sanit Navar. 2003 Jan-Apr;26(1):79-97 [12759713.001]
  • [Cites] N Z Med J. 2003 May 16;116(1174):U437 [12766783.001]
  • [Cites] Surg Endosc. 2003 Jun;17(6):886-90 [12658426.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10 Suppl):S32-43 [14530656.001]
  • [Cites] Am Surg. 2003 Oct;69(10):866-72 [14570365.001]
  • [Cites] Dig Dis. 2003;21(4):315-9 [14752221.001]
  • [Cites] W V Med J. 2003 Sep-Oct;99(5):182-6 [14959509.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] BMC Cancer. 2003 Oct 21;3:27 [14567762.001]
  • [Cites] IARC Sci Publ. 1992;(120):178-861 [1284601.001]
  • [Cites] Semin Surg Oncol. 1994 Jan-Feb;10(1):12-20 [8115781.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1781-5 [12050337.001]
  • (PMID = 15913456.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1173094
  •  go-up   go-down


56. Ebisui C, Ohkubo K, Akitake H, Ohtsuka M, Maekawa T, Yoshioka S, Hama N, Kashiwazaki M, Taniguchi M, Tsujie M, Konishi M, Fujimoto T: [A case of ovarian metastasis from colon cancer successfully treated with multidisciplinary therapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2542-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of ovarian metastasis from colon cancer successfully treated with multidisciplinary therapy].
  • An 80-year-old female patient was undergone sigmoidectomy with D2 lymph node dissection for type 2 sigmoid colon cancer in February 2007.
  • A post operative pathological finding of cancer was SS, N0, P0, H0, M0 (Stage II), curative A.
  • In May 2008, total hysterectomy, bilateral oophorectomy, and partial omentectomy were performed and its pathological finding was metastatic ovarian tumor originating from colon cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Krukenberg Tumor / secondary. Krukenberg Tumor / therapy. Ovarian Neoplasms / secondary. Ovarian Neoplasms / therapy. Sigmoid Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224633.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 1-UFT protocol
  •  go-up   go-down


57. Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, Baumann W, Kreuser ED, Staib L, Link KH: Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol; 2008 Dec;34(12):1316-21
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
  • AIM: Adjuvant chemotherapy is recommended for stage III colon cancer.
  • The aim of this study was to identify important prognostic factors among patients with colon cancer receiving adjuvant 5-FU-based treatment.
  • METHODS: Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined.
  • CONCLUSIONS: Adjuvant 5-FU-based treatment should be performed for at least 6months with a stepwise adjustment of 5-FU doses until toxicity >WHO II.
  • In the future, this may result in adjuvant treatment of stage III colon cancer adjusted for the risk of substages.
  • [MeSH-major] Adenocarcinoma / mortality. Antimetabolites, Antineoplastic / therapeutic use. Colonic Neoplasms / mortality. Fluorouracil / therapeutic use

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313881.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Immunologic Factors; 0 / Interferon-alpha; 12001-76-2 / Vitamin B Complex; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


58. Pasetto LM, Falci C, Basso U, Gasparini G, D'Andrea M, Bonginelli P, Bajetta E, Platania M, Alabiso O, Miraglia S, Bertona E, Oniga F, Biason R, Chetrì MC, Fedele P, Massara G, Romaniello I, Negru ME, Luchena G, Giordano M, Buzzi F, Ricottao R, Sienao S, Monfardini S: Adjuvant treatment for elderly patients with colon cancer. An observational study. Anticancer Res; 2008 Jul-Aug;28(4C):2513-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant treatment for elderly patients with colon cancer. An observational study.
  • BACKGROUND: Adjuvant 5-fluoruracil-based chemotherapy significantly reduces mortality in patients with stage II-III colon cancer, but is less prescribed with rising age.
  • PATIENTS AND METHODS: From January to December 2004, 63 questionnaires on the management of stage II-III resected colon cancer patients aged over 70 years, collected from 10 Italian Centres, were retrospectively examined.
  • Due to the paucity of events, the impact of prognostic factors (patient's age and comorbidity, tumour stage and grade) on DFS and OS could not be assessed.
  • CONCLUSION: An increasing proportion of elderly patients with colon cancer may be treated with a tolerability and OS similar to those observed in the younger population.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751443.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  •  go-up   go-down


59. Suh KW, Kim JH, Kim YB, Kim J, Jeong S: Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer. J Gastrointest Surg; 2005 Mar;9(3):336-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase gene polymorphism as a prognostic factor for colon cancer.
  • Here, we determined the significance of this polymorphism in predicting the clinical outcomes for patients with colon cancer.
  • We reviewed 121 consecutive patients with stage II or III colon cancer who underwent a curative resection.
  • The difference was particularly significant in the patients with stage III disease (41% versus 77%, P=0.0414).
  • Tumor stage and the TS polymorphism were identified as significant prognostic factors by multivariate analysis.
  • We found the TS polymorphism to be a significant and independent prognostic factor for colon cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / mortality. Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / mortality. Thymidylate Synthase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):597-602 [11801762.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1227-34 [9607581.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3A):1515-20 [9673363.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] Clin Colorectal Cancer. 2001 Nov;1(3):175-8; discussion 179-81 [12450432.001]
  • [Cites] Biochim Biophys Acta. 1993 Dec 14;1216(3):409-16 [8268221.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1063-72 [10741735.001]
  • [Cites] Pharmacogenomics J. 2001;1(1):65-70 [11913730.001]
  • [Cites] Biochim Biophys Acta. 1977 Dec 23;473(2):73-92 [145246.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):14-20 [7677801.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1407-12 [7882343.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1653-64 [3049954.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):70-7 [9428481.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2898-904 [12782596.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1243-50 [9607583.001]
  • [Cites] Cancer Lett. 2003 Feb 10;190(1):97-104 [12536082.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1378-84 [10778966.001]
  • [Cites] Cell Struct Funct. 1995 Jun;20(3):191-7 [7586009.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2832-43 [12065560.001]
  • (PMID = 15749593.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


60. Aranda E, Abad A, Carrato A, Cervantes A, Tabernero J, Díaz-Rubio E, TTD Group: Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). Clin Transl Oncol; 2006 Feb;8(2):98-102
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
  • The choice of the most suitable chemotherapy schedule for the adjuvant treatment of colon cancer has been reviewed by the TTD group, as well as the principles of risk assessment for patients with stage II disease.
  • In patients with stage II disease, the indication of chemotherapy must be individualized and based on the patient's risk of recurrence (perforation, obstruction, peritumoral lymphovascular involvement, poorly differentiated histology, number of lymph nodes examined < or = 11, pre-surgical CEA), and comorbidities that can compromise the safety of treatment or survival of the patient.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Algorithms. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Capecitabine. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Randomized Controlled Trials as Topic. Risk Assessment. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Clin Colorectal Cancer. 2005 Mar;4(6):384-9 [15807931.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2936-43 [8523058.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):674-80 [19179549.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1437-43 [11720425.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 16632423.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; 1-UFT protocol; Folfox protocol
  •  go-up   go-down


61. Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC, O'Connell MJ, North Central Cancer Treatment Group: Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer; 2010 Apr 1;116(7):1691-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients.
  • BACKGROUND: : Colon cancers with defective DNA mismatch repair (MMR) have a favorable prognosis and may lack benefit from 5-fluorouracil-based adjuvant chemotherapy.
  • The authors developed models to predict MMR deficiency in sporadic colon cancer patients using routine clinical and pathological data.
  • METHODS: : TNM stage II and III colon carcinomas (n = 982) from 6 5-fluorouracil-based adjuvant therapy trials were analyzed for microsatellite instability and/or MMR protein expression.
  • CONCLUSIONS: : Defective MMR is rare in distal, sporadic colon cancers, which should generally not undergo MMR testing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2359-67 [16710035.001]
  • [Cites] Gut. 2006 Jun;55(6):848-55 [16299036.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):48-56 [17631130.001]
  • [Cites] J Clin Oncol. 2007 Aug 10;25(23):3534-42 [17687158.001]
  • [Cites] Am J Clin Pathol. 2008 Feb;129(2):238-44 [18208804.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2587-93 [18798261.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1079-99 [18773902.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15 [18990764.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5783-8 [18809606.001]
  • [Cites] Eur J Cancer. 2009 Feb;45(3):365-73 [18722765.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2225-31 [10786688.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2025-37 [11066042.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1831-6 [11078760.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2417-22 [11413533.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23 [11535541.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):53-7 [11782358.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1166-70 [11861399.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1711-3 [11919223.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):394-401 [14762775.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] Anticancer Res. 1994 Jul-Aug;14(4B):1657-60 [7979203.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1805-13 [10362805.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2738-44 [16675565.001]
  • [Cites] Am J Gastroenterol. 2006 May;101(5):1104-11 [16696788.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • (PMID = 20186699.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CA / CA104683-02; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / K05 CA142885; United States / NCI NIH HHS / CA / R01 CA104683-02; United States / NCI NIH HHS / CA / N01 CA015083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS163421; NLM/ PMC2855300
  •  go-up   go-down


62. Billingsley KG, Morris AM, Dominitz JA, Matthews B, Dobie S, Barlow W, Wright GE, Baldwin LM: Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship. Arch Surg; 2007 Jan;142(1):23-31; discussion 32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgeon and hospital characteristics as predictors of major adverse outcomes following colon cancer surgery: understanding the volume-outcome relationship.
  • PATIENTS: Patients aged 66 years and older, diagnosed and surgically treated for stage I, II, or III colon cancer between 1992 and 1996 (n = 22 672).
  • [MeSH-major] Adenocarcinoma / surgery. Colonic Neoplasms / surgery. Digestive System Surgical Procedures / utilization. Hospitals / utilization. Outcome Assessment (Health Care)

  • MedlinePlus Health Information. consumer health - Health Facilities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224497.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Henry LR, Lee HO, Lee JS, Klein-Szanto A, Watts P, Ross EA, Chen WT, Cheng JD: Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res; 2007 Mar 15;13(6):1736-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of fibroblast activation protein in patients with colon cancer.
  • PURPOSE: Human fibroblast activation protein (FAP)/seprase is a 97-kDa surface glycoprotein expressed on tumor associated fibroblasts in the majority of epithelial cancers including colon adenocarcinomas.
  • The primary objective of this study was to evaluate the clinical significance of stromal FAP in human colon cancers by immunohistochemisty.
  • EXPERIMENTAL DESIGN: Sections of paraffin-embedded resected primary human colon cancer specimens from 1996 through 2001 within the Fox Chase Cancer Center tumor bank were stained with D8 antibody directed against FAP/seprase.
  • RESULTS: One hundred thirty-eight patients with resected specimens were available for study (mean follow-up, 1,050 days) with 6 (4%) stage I, 52 (38%) stage II, 43 (31%) stage III, and 37 (27%) stage IV patients.
  • Stromal FAP was found to correlate inversely with tumor stage (semiquantitative, P = 0.01; intensity, P = 0.009) and with tumor size of the tumor xenograft model (correlation coefficient, -0.61; P = 0.047), suggesting that stromal FAP may have a greater role in the early development of tumors.
  • CONCLUSION: Our data indicate that patients whose colon tumors have high levels of stromal FAP are more likely to have aggressive disease progression and potential development of metastases or recurrence.
  • It also suggests that the effects of FAP inhibition should be investigated in earlier-stage tumors, given its high levels and potential effect earlier in the course of the disease.
  • [MeSH-major] Adenocarcinoma / genetics. Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Serine Endopeptidases / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363526.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA006927; United States / NCI NIH HHS / CA / CA09035; United States / NCI NIH HHS / CA / CA090468; United States / NCI NIH HHS / CA / CA103991; United States / PHS HHS / / W81XWH-04-1-0709
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


64. Clark-Langone KM, Sangli C, Krishnakumar J, Watson D: Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay. BMC Cancer; 2010;10:691
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX Colon Cancer Assay.
  • BACKGROUND: The Oncotype DX Colon Cancer Assay is a new diagnostic test for determining the likelihood of recurrence in stage II colon cancer patients after surgical resection using fixed paraffin embedded (FPE) primary colon tumor tissue.
  • By capturing the biology underlying each patient's tumor, the Oncotype DX Colon Cancer Assay provides a Recurrence Score (RS) that reflects an individualized risk of disease recurrence.
  • CONCLUSIONS: Analytical performance characteristics shown here for both individual genes and gene groups in the Oncotype DX Colon Cancer Assay demonstrate consistent translation of specific biology of individual tumors into clinically useful diagnostic information.
  • The results of these studies illustrate how the analytical capability of the Oncotype DX Colon Cancer Assay has enabled clinical validation of a test to determine individualized recurrence risk after colon cancer surgery.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Genetic Testing / methods. Molecular Diagnostic Techniques. Neoplasm Recurrence, Local / genetics. Precision Medicine. Reverse Transcriptase Polymerase Chain Reaction


65. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, Washington MK, Heslin MJ, Coffey RJ, Yeatman TJ, Shyr Y, Beauchamp RD: Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology; 2010 Mar;138(3):958-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer.
  • BACKGROUND & AIMS: Staging inadequately predicts metastatic risk in patients with colon cancer.
  • We used a gene expression profile derived from invasive, murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify patients with colon cancer at risk of recurrence.
  • The metastasis-associated gene expression profile developed from the mouse model was refined with comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer.
  • RESULTS: A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathologic stages and specifically in stage II and stage III patients.
  • For example, among stage III patients, a high score translated to increased relative risk of cancer recurrence (hazard ratio, 4.7; 95% confidence interval, 1.566-14.05).
  • Furthermore, the metastasis score identified patients with stage III disease whose 5-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not increase survival time.
  • CONCLUSION: A gene expression profile identified from an experimental model of colon cancer metastasis predicted cancer recurrence and death, independently of conventional measures, in patients with colon cancer.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [Cites] Acta Oncol. 2001;40(2-3):282-308 [11441937.001]
  • [Cites] N Engl J Med. 2001 Feb 22;344(8):539-48 [11207349.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] Clin Exp Metastasis. 2003;20(8):733-44 [14713107.001]
  • [Cites] PLoS Biol. 2004 Feb;2(2):E7 [14737219.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1564-71 [15051756.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):757-68 [10753213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19432-7 [19050079.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2395-8 [11289103.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S51-5 [15508103.001]
  • [Cites] Clin Oncol. 1976 Jun;2(2):131-40 [182425.001]
  • [Cites] J Natl Cancer Inst. 1976 Nov;57(5):1199-202 [1003551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6226-30 [6947225.001]
  • [Cites] JAMA. 1982 May 14;247(18):2543-6 [7069920.001]
  • [Cites] J Natl Cancer Inst. 1986 Feb;76(2):309-22 [3484792.001]
  • [Cites] Control Clin Trials. 1993 Aug;14(4):266-85 [8365193.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Nat Genet. 2004 Dec;36(12):1306-11 [15565109.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] Bioinformatics. 2005 May 1;21(9):2067-75 [15657102.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3526-35 [15908663.001]
  • [Cites] J Clin Invest. 2006 Jun;116(6):1582-95 [16710476.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4685-91 [16966692.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507 [17255271.001]
  • [Cites] Lancet. 2007 Dec 15;370(9604):2020-9 [18083404.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cochrane Database Syst Rev. 2008;(3):CD005390 [18646127.001]
  • [Cites] Cancer Lett. 2008 Aug 28;267(2):197-203 [18406516.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Mol Ther. 2001 Oct;4(4):297-306 [11592831.001]
  • (PMID = 19914252.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE17538
  • [Grant] United States / NCI NIH HHS / CA / CA46413; United States / NCI NIH HHS / CA / CA077839; United States / NCI NIH HHS / CA / P50 CA128323; United States / NIDDK NIH HHS / DK / DK52334; United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01 CA046413; United States / NCI NIH HHS / CA / T32 CA106183; United States / NCI NIH HHS / CA / CA112215; United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / CA126588; United States / NCRR NIH HHS / RR / TL1 RR024978; United States / NCI NIH HHS / CA / U24 CA126588; United States / NCI NIH HHS / CA / P01 CA077839; United States / NCI NIH HHS / CA / CA106183; United States / NCI NIH HHS / CA / CA084239; United States / NCI NIH HHS / CA / U01 CA084239; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / R01 CA069457; United States / NCI NIH HHS / CA / CA95103; United States / NIDDK NIH HHS / DK / R01 DK052334; United States / NCI NIH HHS / CA / CA128323; United States / NCI NIH HHS / CA / CA068485; United States / NCI NIH HHS / CA / CA69457
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS388171; NLM/ PMC3388775
  •  go-up   go-down


66. Minicozzi A, Veraldi GF, Borzellino G: Minimally invasive treatment of portal hypertension, abdominal aortic aneurysm, and colon cancer: a case report. Surg Laparosc Endosc Percutan Tech; 2010 Aug;20(4):281-3
Genetic Alliance. consumer health - Abdominal Aortic Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive treatment of portal hypertension, abdominal aortic aneurysm, and colon cancer: a case report.
  • We report the case of a cirrhotic patient with portal hypertension, abdominal aortic aneurysm (AAA), and right colon cancer.
  • After neoadjuvant transjugular intrahepatic portosystemic shunt, we performed 1-stage endovascular aneurysm repair and laparoscopic right colectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Aortic Aneurysm, Abdominal / surgery. Colonic Neoplasms / surgery. Endovascular Procedures. Hypertension, Portal / surgery. Laparoscopy

  • Genetic Alliance. consumer health - Portal hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20729703.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ: Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology; 2009 Oct;137(4):1270-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma.
  • We investigated whether the intratumoral densities of FoxP3(+) and effector CD3(+) lymphocytes are associated with prognosis of patients with colon cancer.
  • METHODS: FoxP3 and CD3 expression and location were determined in stage II and III colon carcinomas (n = 160) and normal mucosa (n = 25) by immunohistochemistry; CD4 and FoxP3 were localized by dual immunofluorescence microscopy.
  • By multivariate analysis, a low CD3(+)/FoxP3(+) cell ratio (P= .0318) and low numbers of CD3(+) T cells (P = .0397) predicted shorter DFS times and were stronger prognostic variables than tumor stage or number of lymph node metastases.
  • CONCLUSIONS: A low intraepithelial CD3(+)/FoxP3(+) cell ratio and reduced numbers of CD3(+) T cells were associated with shorter patient survival time, indicating the importance of an effector to Treg cell ratio in colon cancer prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] Cancer Immunol Immunother. 2009 Jan;58(1):135-44 [18488217.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 4;91(15):1295-303 [10433618.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):779-91 [15753211.001]
  • [Cites] Nat Immunol. 2005 Apr;6(4):331-7 [15785758.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9253-7 [15961541.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8326-31 [16322292.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1144-51 [16489067.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Annu Rev Immunol. 2006;24:209-26 [16551248.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1935-45 [16778987.001]
  • [Cites] Clin Colorectal Cancer. 2006 Jul;6(2):133-9 [16945169.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):729-37 [16952542.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10145-52 [17047079.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5373-80 [17135638.001]
  • [Cites] Cancer. 2006 Dec 15;107(12):2866-72 [17099880.001]
  • [Cites] PLoS One. 2006;1:e129 [17205133.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):624-31 [17223543.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1232-8 [17187355.001]
  • [Cites] Cancer Immun. 2007;7:7 [17388261.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2075-81 [17404089.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):68-73 [11138001.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):297-304 [11438476.001]
  • [Cites] Clin Exp Immunol. 2002 Jan;127(1):85-91 [11882037.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1735-43 [11919229.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):606-12 [12576425.001]
  • [Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]
  • [Cites] Nat Rev Immunol. 2003 Mar;3(3):253-7 [12658273.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(4):469-75 [12751377.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1089-99 [12942579.001]
  • [Cites] Jpn J Clin Oncol. 2004 Feb;34(2):90-8 [15067103.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5287-96 [15100267.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] J Exp Med. 2004 Sep 20;200(6):771-82 [15381730.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Int Immunol. 2004 Nov;16(11):1643-56 [15466453.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1711-7 [15494715.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Dec;20(12):1485-7 [6238826.001]
  • [Cites] Cell Immunol. 1993 Jan;146(1):107-16 [7678783.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1481-7 [9593786.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Gastroenterology. 2007 Jun;132(7):2328-39 [17570208.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2586-93 [17577038.001]
  • [Cites] Semin Cancer Biol. 2007 Aug;17(4):275-87 [17662614.001]
  • [Cites] Immunity. 2007 Oct;27(4):635-46 [17919943.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):415-20 [18037158.001]
  • [Cites] Br J Cancer. 2008 Apr 8;98(7):1258-63 [18349839.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):988-97 [18395080.001]
  • [Cites] Eur J Hum Genet. 1999 May-Jun;7(4):407-8 [10352929.001]
  • (PMID = 19577568.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA15083; United States / NCI NIH HHS / CA / R01 CA104683-04; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / CA104683-02; United States / NCI NIH HHS / CA / R01 CA104683; United States / NCI NIH HHS / CA / CA104683-04; United States / NCI NIH HHS / CA / N01 CA015083
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  • [Other-IDs] NLM/ NIHMS130072; NLM/ PMC2873775
  •  go-up   go-down


68. van Leeuwen BL, Påhlman L, Gunnarsson U, Sjövall A, Martling A: The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region. Crit Rev Oncol Hematol; 2008 Sep;67(3):229-36

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region.
  • RATIONALE: The aim of this study was to assess whether there are differences in treatment strategy and outcome between different age cohorts among men and women with colon cancer.
  • METHODS: All patients with colon cancer included in the regional quality registry in Uppsala/Orebro and Stockholm between 1996 and December 2004 were analysed (n=11002).
  • RESULTS: Overall and cancer-specific survival decreased with increasing age for stages II and III colon cancer but was not influenced by gender.
  • Older patients with stage III tumours were less likely to be referred for chemotherapeutic treatment and there was a decrease in cancer-specific survival with increasing age, from 63.7% to 51.0% to 38.4% in the three age groups.
  • [MeSH-minor] Adenocarcinoma. Age Distribution. Age Factors. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Registries. Sex Factors. Survival Analysis. Sweden. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18440820.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


69. Benevolo M, Mottolese M, Piperno G, Sperduti I, Cione A, Sibilio L, Martayan A, Donnorso RP, Cosimelli M, Giacomini P: HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant. Am J Surg Pathol; 2007 Jan;31(1):76-84
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-A, -B, -C expression in colon carcinoma mimics that of the normal colonic mucosa and is prognostically relevant.
  • Herein, monoclonal antibodies with preferential reactivity for HLA-A, HLA-B, and HLA-C (HCA2, HC10, and L31) were used to stain an archival collection of 291 formalin-fixed/paraffin-embedded tissues, comprising neoplastic lesions from stages II and III colon carcinoma patients (n=165), and the uninvolved, morphologically normal mucosae from a subset (n=126) of these patients.
  • Deviations from the expression in the normal paired mucosa (both increases and decreases) of HCA2-reactive class I molecules (possibly HLA-A), and down-regulation of L31-reactive class I molecules (possibly HLA-C), particularly in tumors from stage II patients, correlated with poor 5-year overall and disease-free survival, hazard risk ranging from 2 to 6, approximately.
  • Thus, a paired immunohistochemical comparison reveals a novel immune evasion strategy that may impact on the prognosis of colon carcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Histocompatibility Antigens Class I / metabolism. Intestinal Mucosa / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17197922.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


70. Dillman RO, Aaron K, Heinemann FS, McClure SE: Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance. Cancer; 2009 May 1;115(9):1840-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of 12 or more lymph nodes in resected colon cancer specimens as an indicator of quality performance.
  • BACKGROUND: : Identification of > or =12 lymph nodes in resected colon cancer specimens has been endorsed as a quality indicator.
  • METHODS: : The Hoag Hospital cancer registry was used to identify patients diagnosed with colon cancer.
  • The proportion of colon cancer specimens for which > or =12 lymph nodes were identified was determined by anatomic location, stage of disease, patient age, and operating surgeon.
  • Survival was correlated with stage and with whether > or =12 lymph nodes were identified.
  • RESULTS: : Pathology procedural changes in 1998 were associated with an increase in the average number of lymph nodes identified from 8.0 to 14.5 (P < .0001); therefore, analysis was limited to 574 patients who underwent surgical resection of colon adenocarcinoma during 1998 to 2005.
  • Identification of > or =12 lymph nodes was associated with better survival for patients with stage I (P = .016) and stage II (P = .021) disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208427.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Givalos N, Gakiopoulou H, Skliri M, Bousboukea K, Konstantinidou AE, Korkolopoulou P, Lelouda M, Kouraklis G, Patsouris E, Karatzas G: Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer. Mod Pathol; 2007 Feb;20(2):159-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer.
  • Experimental studies in colon cancer cell lines have shown that RPA protein may be the target of cytotoxins designed to inhibit cellular proliferation.
  • This is the first study to investigate the expression of RPA1 and RPA2 subunits of RPA protein and assess their prognostic value in colon cancer patients.
  • We analyzed immunohistochemically the expression of RPA1 and RPA2 proteins in a series of 130 colon cancer resection specimens in relation to conventional clinicopathological parameters and patients' survival.
  • Statistical significant positive associations emerged between: (a) RPA1 and RPA2 protein expressions (P=0.0001), (b) RPA1 and RPA2 labelling indices (LIs) and advanced stage of the disease (P=0.001 and 0.003, respectively), (c) RPA1 and RPA2 LIs and the presence of lymph node metastasis (P=0.002 and 0.004, respectively), (d) RPA1 LI and the number of infiltrated lymph nodes (P=0.021), (e) RPA2 LI and histological grade of carcinomas (P=0.05).
  • Statistical significant differences according to the expression of RPA1 and RPA2 proteins were also noticed in the survival of stage II (P<0.00001 and 0.0016, respectively) and stage III (P=0.0029 and 0.0079, respectively) patients.
  • In conclusion, RPA1 and RPA2 proteins appear to be useful prognostic indicators in colon cancer patients and attractive therapeutic targets for regulation by tumor suppressors or other proteins involved in the control of cell proliferation.
  • [MeSH-major] Adenocarcinoma / metabolism. Colon / metabolism. Colonic Neoplasms / metabolism. Replication Protein A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361204.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RPA1 protein, human; 0 / Replication Protein A; EC 2.7.7.7 / RPA2 protein, human
  •  go-up   go-down


72. Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T, Möller P: Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut; 2005 May;54(5):661-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.
  • BACKGROUND: Loss of CD95 expression in tumour cells occurs frequently in colon carcinoma and may be associated with disease progression.
  • AIMS: We aimed at further exploring the functional role and prognostic significance of the CD95/CD95L death inducing system in colon carcinomas.
  • PATIENTS AND METHODS: CD95 and CD95L expression was examined by immunohistochemistry in 128 R0 resected UICC (International Union against Cancer) stage II/III colon carcinomas and correlated with disease free survival.
  • Tumour infiltrating lymphocytes (TIL) were the major source of CD95L in colon carcinomas.
  • Moreover, a high rate of CD95L+TIL correlated with prolonged disease free survival in patients with UICC stage II (p = 0.05) but not in those with stage III.
  • CONCLUSIONS: Loss of CD95 in tumour cells may be an independent prognostic factor in colon carcinomas.
  • The CD95L counterattack is not a relevant feature in colon carcinoma but CD95L+TIL may contribute to tumour control in the early stages of the disease, exerting a concurrent selection pressure in the direction of CD95 abrogation/resistance.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, CD95 / metabolism. Biomarkers, Tumor / metabolism. Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Nov;30(11):1309-13 [10571510.001]
  • [Cites] Cell Death Differ. 2001 Mar;8(3):273-8 [11319610.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5023-7 [10799856.001]
  • [Cites] J Pathol. 2001 May;194(1):15-9 [11329136.001]
  • [Cites] J Immunol. 2001 Aug 15;167(4):2068-73 [11489989.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):139-48 [12204534.001]
  • [Cites] J Immunol. 2003 Jun 15;170(12):5973-80 [12794124.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):708-15 [12949717.001]
  • [Cites] J Immunol. 2003 Oct 15;171(8):4164-74 [14530339.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):930-6 [7226044.001]
  • [Cites] Cell. 1991 Jul 26;66(2):233-43 [1713127.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10709-15 [1375228.001]
  • [Cites] Lab Invest. 1993 Oct;69(4):415-29 [7693996.001]
  • [Cites] Int J Cancer. 1994 May 1;57(3):371-7 [8168998.001]
  • [Cites] Int J Cancer. 1996 Sep 4;67(5):709-14 [8782663.001]
  • [Cites] Science. 1996 Nov 22;274(5291):1363-6 [8910274.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1075-82 [9064324.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):1149-54 [9064331.001]
  • [Cites] Cell. 1997 Feb 7;88(3):355-65 [9039262.001]
  • [Cites] Gastroenterology. 1997 Jul;113(1):160-7 [9207274.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):526-34 [9458101.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] J Exp Med. 1998 Nov 2;188(9):1717-23 [9802983.001]
  • [Cites] J Pathol. 1998 Nov;186(3):240-6 [10211111.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1025-32 [10510092.001]
  • [Cites] J Exp Med. 1999 Oct 4;190(7):1033-8 [10510093.001]
  • [Cites] J Immunol. 2000 May 1;164(9):4941-54 [10779805.001]
  • (PMID = 15831912.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Ligands; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ PMC1774512
  •  go-up   go-down


73. Takahashi H, Sawai H, Matsuo Y, Funahashi H, Satoh M, Okada Y, Inagaki H, Takeyama H, Manabe T: Reactive lymphoid hyperplasia of the liver in a patient with colon cancer: report of two cases. BMC Gastroenterol; 2006;6:25
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reactive lymphoid hyperplasia of the liver in a patient with colon cancer: report of two cases.
  • BACKGROUND: Reactive lymphoid hyperplasia (RLH) of the liver is very rarely reported, and we encountered two cases of RLH of the liver in a patient with colon cancer.
  • CASE PRESENTATION: In the first case, a 77-year-old woman was admitted for the surgical removal of a ascending colon cancer.
  • In the second case, a 64-year-old woman who had a radical right hemicolectomy for stage II ascending colon cancer 10 years ago was admitted with dysuria.
  • CONCLUSION: Our two cases were the first report of RLH of the liver accompanying colon cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Colonic Neoplasms / epidemiology. Liver Diseases / epidemiology. Pseudolymphoma / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):587-97 [10757408.001]
  • [Cites] Hum Pathol. 2005 May;36(5):505-11 [15948117.001]
  • [Cites] Scand J Rheumatol. 2001;30(2):117-9 [11324789.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jul;177(1):71-5 [11418401.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2004 Jul;101(7):772-8 [15293728.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jan;105(1):46-9 [6893912.001]
  • [Cites] Zentralbl Allg Pathol. 1987;133(6):565-8 [3328445.001]
  • [Cites] Hum Pathol. 1991 Jul;22(7):724-6 [2071115.001]
  • [Cites] Br J Ophthalmol. 1991 Dec;75(12):722-5 [1768660.001]
  • [Cites] Pathol Int. 1994 Sep;44(9):704-11 [7804433.001]
  • [Cites] Pathol Res Pract. 1996 Feb;192(2):166-9; discussion 170-1 [8692718.001]
  • [Cites] J Hepatol. 1997 Jan;26(1):209-14 [9148014.001]
  • [Cites] J Gastroenterol Hepatol. 1999 Feb;14(2):163-7 [10029298.001]
  • [Cites] Am J Surg Pathol. 1999 Mar;23(3):302-8 [10078921.001]
  • [Cites] Arch Pathol Lab Med. 2001 Apr;125(4):577-8 [11260645.001]
  • (PMID = 16965640.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1579220
  •  go-up   go-down


74. Grade M, Hörmann P, Becker S, Hummon AB, Wangsa D, Varma S, Simon R, Liersch T, Becker H, Difilippantonio MJ, Ghadimi BM, Ried T: Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res; 2007 Jan 1;67(1):41-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas.
  • To characterize patterns of global transcriptional deregulation in primary colon carcinomas, we did gene expression profiling of 73 tumors [Unio Internationale Contra Cancrum stage II (n = 33) and stage III (n = 40)] using oligonucleotide microarrays.
  • Seventeen genes had a >5-fold average expression difference between normal colon mucosa and carcinomas, including up-regulation of MYC and of HMGA1, a putative oncogene.
  • Finally, we established a relationship between specific genomic imbalances, which were mapped for 32 of the analyzed colon tumors by comparative genomic hybridization, and alterations of global transcriptional activity.
  • The systematic comparison of colon and rectal carcinomas revealed a significant overlap of genomic imbalances and transcriptional deregulation, including activation of the Wnt/beta-catenin signaling cascade, suggesting similar pathogenic pathways.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Aneuploidy. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon / metabolism. Colon / physiology. Female. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genome, Human. Humans. Intestinal Mucosa / metabolism. Intestinal Mucosa / physiology. Lymphatic Metastasis. Male. Middle Aged. Multigene Family. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17210682.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS663105; NLM/ PMC4721580
  •  go-up   go-down


75. Chen HH, Chakravarty K D, Wang JY, Changchien CR, Tang R: Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution. Int J Colorectal Dis; 2010 Nov;25(11):1333-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological examination of 12 regional lymph nodes and long-term survival in stages I-III colon cancer patients: an analysis of 2,056 consecutive patients in two branches of same institution.
  • PURPOSE: Pathologic examination of at least 12 lymph nodes (LNs) is widely accepted as a standard for colon cancer surgery.
  • METHODS: Patients with stages I-III adenocarcinoma of the colon between 1998 and 2003 were identified from the Chang Gung Colorectal Tumor Registry in two branches (Linkou and Kaohsiung branches) of same institution.
  • Younger age, right hemicolectomy, larger tumor, higher tumor stage, higher caseload of surgeons, and patients at Linkou branch with an odds ratio (OR) as high as 23 (95% CI, 17-31) were independently associated with a higher frequency of ≥12 examined nodes.
  • Patients with examined node number of <12 had a greater risk of recurrence within stages II and III (stage II: adjusted OR 1.88, 95% CI 1.27-2.79; stage III: adjusted OR 1.58, 95% CI 1.15-2.17) but not within stage I (OR 0.73, 95% CI 0.23-2.24).
  • CONCLUSIONS: The results confirm that factors influencing nodal harvest are multifactorial and the examined LN number of 12 or more is associated with an increased long-term survival in stages II-III colon cancer.
  • It is possible to adequately sample and examine a sufficient number of nodes in the majority of colon cancer specimens by standardized conventional methods.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:62-73; discussion 73-4 [10911906.001]
  • [Cites] Dis Colon Rectum. 2009 Feb;52(2):260-7 [19279421.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2896-900 [10561368.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2009 Apr;249(4):602-7 [19300229.001]
  • [Cites] J Gastroenterol Hepatol. 1991 Jul-Aug;6(4):325-44 [1912440.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):666-72 [9708929.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):858-63 [17522509.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Ann Surg. 2007 Jun;245(6):846-57 [17522508.001]
  • [Cites] Colorectal Dis. 2008 Feb;10(2):157-64 [17477849.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):585-93 [19116751.001]
  • [Cites] J Gastrointest Surg. 2002 Nov-Dec;6(6):883-88; discussion 889-90 [12504228.001]
  • [Cites] J Clin Oncol. 2009 Dec 20;27(36):6166-71 [19901106.001]
  • [Cites] Am J Surg. 2007 Sep;194(3):349-54 [17693281.001]
  • [Cites] Arch Surg. 2008 Nov;143(11):1050-5; discussion 1055 [19015462.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):272-9 [15661553.001]
  • [Cites] J Natl Cancer Inst. 2007 Mar 21;99(6):433-41 [17374833.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):624-8; discussion 628-30 [15383790.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2912-9 [12885809.001]
  • [Cites] JAMA. 2007 Nov 14;298(18):2149-54 [18000198.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):46-51 [17985187.001]
  • [Cites] Ann Surg Oncol. 2003 Apr;10(3):213-8 [12679304.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):452 [11466702.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):682-7 [8608876.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):878-83 [16418493.001]
  • [Cites] J Am Coll Surg. 2008 Feb;206(2):247-54 [18222376.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71 [12513963.001]
  • [Cites] Arch Surg. 2010 Jan;145(1):12-7 [20083749.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):458-63 [11923600.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(14):2071-8 [16125926.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):219-25 [15687365.001]
  • (PMID = 20676662.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Angitapalli R, Litwin AM, Kumar PR, Nasser E, Lombardo J, Mashtare T, Wilding GE, Fakih MG: Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology; 2009;76(5):363-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
  • BACKGROUND: The impact of adjuvant chemotherapy on hepatic function and portal hypertension in patients with stages II-III colon cancer has not been previously described.
  • METHODS: Stage II-III colorectal cancer patients treated with adjuvant FOLFOX or fluorouracil/leucovorin (5-FU/LV) at Roswell Park Cancer Institute between 2002 and 2006 were identified.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. Splenomegaly / chemically induced

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Splenomegaly.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19321964.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


77. Min BS, Kim NK, Ko YT, Baek SH, Lee KY, Sohn SK, Cho CH, Kang DR: Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study. Hepatogastroenterology; 2009 Jul-Aug;56(93):984-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of signet-ring cell carcinoma of the colon and rectum: a case-matched study.
  • BACKGROUND/AIMS: Primary colorectal signet-ring cell carcinoma (SRC) is a rare type of mucin-containing adenocarcinoma and little information exists about its clinicopathological features.
  • METHODS: The clinicopathological features of 27 patients with primary colorectal SRC were compared with non-signet-ring cell mucinous carcinoma (MC) and non-mucinous adenocarcinoma (NMC).
  • In stage II and III, SRC was found to be associated with a worse cancer-specific survival and a higher systemic recurrence rates than either NMC or MC.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Signet Ring Cell / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19760925.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


78. Mizushima T, Ito T, Mizuno H, Souma Y, Kainuma S, Yamanaka H, Ozawa H, Kanou T, Nakamori Y, Iwase K: [A case of recurrent colon cancer responding completely to uracil/tegafur (UFT) plus oral leucovorin (LV) therapy]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2129-31
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent colon cancer responding completely to uracil/tegafur (UFT) plus oral leucovorin (LV) therapy].
  • Histological diagnosis was moderately differentiated adenocarcinoma, ss, n(-), P 0, H 0, M (-), stage II.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352943.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / UFT(R) drug; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; Q573I9DVLP / Leucovorin
  •  go-up   go-down


79. You YN, Baxter NN, Stewart A, Nelson H: Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg; 2007 May;245(5):726-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database.
  • SUMMARY BACKGROUND DATA: Despite the lack of level I/level II evidence supporting its oncologic adequacy, LE is performed for stage I rectal cancer.
  • METHODS: Surgical therapy for 35,179 patients with stage I rectal cancer diagnosed in 1989 to 2003 was examined over time, utilizing the National Cancer Database.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Mar;231(3):345-51 [10714627.001]
  • [Cites] Dis Colon Rectum. 2002 Jul;45(7):875-9 [12130873.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):896-902 [11550163.001]
  • [Cites] Dis Colon Rectum. 2001 Sep;44(9):1345-61 [11584215.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] Pathol Oncol Res. 2002;8(1):7-17 [11994757.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):522-29; discussion 529-30 [12368681.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):983-93 [12507204.001]
  • [Cites] Br J Surg. 1985 Sep;72 Suppl:S54-6 [4041764.001]
  • [Cites] Dis Colon Rectum. 1986 Jun;29(6):374-7 [3709314.001]
  • [Cites] Dis Colon Rectum. 1992 Feb;35(2):131-6 [1735314.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] World J Surg. 1997 Sep;21(7):706-14 [9276701.001]
  • [Cites] Am J Surg. 1998 May;175(5):360-3 [9600277.001]
  • [Cites] Semin Surg Oncol. 1998 Sep;15(2):101-13 [9730416.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2408-18 [9840542.001]
  • [Cites] Br J Surg. 1999 Jan;86(1):17-28 [10027354.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):49-54 [10400036.001]
  • [Cites] Dis Colon Rectum. 1999 Jul;42(7):881-5 [10411434.001]
  • [Cites] Arch Surg. 1999 Aug;134(8):863-7; discussion 867-8 [10443810.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):312-8 [10458248.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1773-9 [15622568.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):429-37 [15747069.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4905-12 [16051945.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6199-206 [16135487.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):472-7; discussion 477-9 [16192807.001]
  • [Cites] JAMA. 2005 Nov 23;294(20):2587-93 [16304072.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • (PMID = 17457165.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA101695; United States / NCI NIH HHS / CA / U10 CA076001; United States / NCI NIH HHS / CA / T32 CA 101695; United States / NCI NIH HHS / CA / U01 CA 76001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1877081
  •  go-up   go-down


80. Chang SC, Lin JK, Lin TC, Liang WY: Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int J Oncol; 2005 Jan;26(1):65-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma.
  • Of these, 20 were stage I (12%), 54 stage II (32.3%), 58 stage III (34.7%), and 35 stage IV (21%).
  • Genetic p53 alterations were associated with advanced tumor stage and tumor differentiation.
  • Of 132 potentially cured patients, 3-year disease-free survival (DFS) was affected by: advanced TNM stage (I, II, III: 90%, 84%, and 41%), genetic p53 alteration (89% vs. 43%), intratumoral p53 accumulation (71% vs. 56%), and preoperative CEA level >5 ng/ml (74% vs. 58%).
  • In multivariate analysis, genetic alteration of p53 was the most significant independent prognostic factor [hazard ratio (HR) = 6.09; 95% confidence interval (CI): 2.45-15.11], followed by advanced tumor stage (HR = 3.93; 95% CI: 2.14-7.23), and preoperative CEA >5 ng/ml (HR = 1.98; 95% CI: 1.12-3.17).
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Colorectal Neoplasms / diagnosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15586226.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


81. Velenik V, Anderluh F, Oblak I, Strojan P, Zakotnik B: Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J; 2006 Oct;47(5):693-700
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
  • METHODS: Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum entered the prospective phase II study.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Radiation-Sensitizing Agents / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] Bioorg Med Chem. 2000 Jul;8(7):1697-706 [10976516.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(5):597-604 [11290435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):675-9 [12062611.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):415-24 [12142171.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):403-8 [12243814.001]
  • [Cites] Clin Ther. 2004 Apr;26(4):579-89 [15189755.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):131-9 [9075745.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-8-S18-18 [9420016.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):301-8 [9440757.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • (PMID = 17042060.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Radiation-Sensitizing Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2080466
  •  go-up   go-down


82. Widder J, Herbst F, Dobrowsky W, Schmid R, Pokrajac B, Jech B, Chiari C, Stift A, Maier A, Karner-Hanusch J, Teleky B, Wrba F, Jakesz R, Poetter R: Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II). Br J Cancer; 2005 Apr 11;92(7):1209-14
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative short-term radiation therapy (25 Gy, 2.5 Gy twice daily) for primary resectable rectal cancer (phase II).
  • 1) with clinical T3Nx rectal adenocarcinoma received preoperative pelvic radiation therapy with single fractions of 2.5 Gy twice daily (interval 6 h between fractions) to a total dose of 25 Gy within 1 week.
  • Postoperative histology revealed UICC stage I in 33%, stage II in 26%, stage III in 34%, and stage IV in 7% of the patients.
  • Disease-specific and disease-free survivals at 4 years (excluding stage IV) were 82 and 69%, respectively.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Neoplasm Recurrence, Local. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):281-7 [9069298.001]
  • [Cites] Dis Colon Rectum. 1998 May;41(5):543-9; discussion 549-51 [9593234.001]
  • [Cites] Acta Oncol. 1999;38(7):883-93 [10606418.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] JAMA. 2000 Aug 23-30;284(8):1008-15 [10944647.001]
  • [Cites] Radiother Oncol. 2000 Sep;56(3):341-7 [10974384.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):497-504 [11229667.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Eur J Cancer. 2002 Jul;38(11):1429-36 [12110487.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4361-7 [12409336.001]
  • [Cites] Br Med Bull. 2002;64:141-57 [12421731.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Lancet. 1993 Feb 20;341(8843):457-60 [8094488.001]
  • [Cites] Radiother Oncol. 1997 Aug;44(2):123-36 [9288840.001]
  • (PMID = 15785745.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361979
  •  go-up   go-down


83. Papagiorgis P, Oikonomakis I, Karapanagiotou I, Wexner SD, Nikiteas N: The impact of tumor location on the histopathologic expression of colorectal cancer. J BUON; 2006 Jul-Sep;11(3):317-21
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cancer of the colon and rectum has been classically viewed as the same disease entity.
  • Since tumor pathology and staging is the major determinant of the disease outcome, comparison of these parameters between right and left colon cancer is reasonably expected to contribute to a better understanding of the nature of the adenocarcinoma of the colon.
  • Patients were divided into two groups according to the location of the tumor (right or left colon) and pathology between the two groups was compared.
  • Sixty individuals had right colon cancer, while 124 subjects had left colon lesions.
  • Dukes' A (stage I) colon cancer had statistically significant higher incidence in left colon lesions (p=0.0084).
  • Conversely, Dukes' C(stage III) tumors presented more often in the right colon (p=0.029).
  • Grade III lesions showed a clear superiority for the right colon (p=0.0014), while grade II lesions were more commonly found in the left colon (p=0.0201).
  • Grade III lesions were more common in the right colon (p=0.0200) when early colonic cancers (stage 0,I and II pooled together) were compared.
  • CONCLUSION: A shift in severity towards the right colon has been documented both in terms of stage and grade.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309156.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


84. Silvéra L, Galula G, Tiret E, Louvet C, Leroux JL, Trutt B: Assessment of management practices for colonic cancer in the Paris metropolitan area in 2002. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):852-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the management of patients aged 18 years or older with colonic adenocarcinoma (including the rectosigmoid junction), compared with French guidelines (ANAES and SOR).
  • METHODS: This retrospective study carried out in 2003 by the Ile-de-France regional union of health insurance funds from hospital discharge and operative and pathology reports of patients exempted from copayment between April 2001 and March 2002.
  • 37.7% of stage II patients had chemotherapy while 10.8% of stage III and 9.8% of stage IV patients did not.
  • CONCLUSION: Implementation of guidelines for the management of colon cancer can be improved, notably regarding pathologic analysis and indications of chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Colonic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Colon / pathology. Data Collection. Data Interpretation, Statistical. Female. Guideline Adherence. Humans. Liver Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / therapy. Paris. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885869.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] France
  •  go-up   go-down


85. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • Invasive adenocarcinoma was found on histological analysis of the colectomy specimen in 14 out of 63 cases (22%), standard error of the proportion 0.052.
  • Staging of the 14 cancers were I (n = 6, 43%), II (n = 3, 21%), III ( = 4, 29%), and IV (n = 1, 7%).
  • Neither dysplasia on endoscopic biopsy nor lesion diameter was predictive of adenocarcinoma.
  • Eight out of 23 (35%) patients with dysplasia on endoscopic biopsy had adenocarcinoma on final pathology versus 6/40 (15%) with no dysplasia (p = 0.114, Fisher's exact test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


86. Fujita S, Yamamoto S, Akasu T, Moriya Y, Taniguchi H, Shimoda T: Quantification of CD10 mRNA in colorectal cancer and relationship between mRNA expression and liver metastasis. Anticancer Res; 2007 Sep-Oct;27(5A):3307-11
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TIN was higher in colon, pN1/pN2, stage III and IV, and well- or moderately-differentiated adenocarcinoma than in rectum, pNO, stage I and II, and poorly-differentiated or mucinous adenocarcinoma, respectively.
  • Although CD10 mRNA was associated with invasion depth, lymph node status and TNM stage, it was not associated with prognosis.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / immunology. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970075.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


87. Nash GM, Gimbel M, Cohen AM, Zeng ZS, Ndubuisi MI, Nathanson DR, Ott J, Barany F, Paty PB: KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann Surg Oncol; 2010 Feb;17(2):416-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: MSI and KRAS mutation status were assessed in 532 primary adenocarcinomas (stage I-IV) from patients treated by colon resection.
  • MSI was more common in early-stage disease (I, 15%; II, 21%; III, 10%; IV, 2%; P = 0.0001).
  • Prevalence of KRAS mutation did not vary with stage (I, 36%; II, 34%; III, 35%; IV, 40%; P = ns).
  • Using Cox regression analysis MSI, KRAS mutation, and stage were strong independent predictors of survival in the entire patient population.
  • A high-mortality group with MSS/KRAS-mutant tumors was identified within the stage I and II cohort.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19813061.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA065930; United States / NCI NIH HHS / CA / 2 P01 CA65930-05A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS674393; NLM/ PMC4380015
  •  go-up   go-down


88. Hamada M, Ozaki K, Iwata J, Nishioka Y, Horimi T: A case of rectosigmoid cancer metastasizing to a fistula in ano. Jpn J Clin Oncol; 2005 Nov;35(11):676-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete colonoscopy revealed an ulcerative tumor in the rectosigmoid colon.
  • The post-operative pathological diagnosis was rectosigmoid cancer, Type 2, T2, N0, M0, stage II.
  • Pathological diagnosis of the excised fistula revealed well-differentiated adenocarcinoma; identical to the colon tumor.
  • We diagnosed this tumor as metastatic adenocarcinoma from a rectosigmoid cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Anus Neoplasms / secondary. Rectal Fistula / pathology. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275674.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


89. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • On histopathology, there were 361 adenocarcinomas, including 138 well-differentiated, 201 moderately differentiated, 11 poorly differentiated, 11 mucinous adenocarcinoma, and 10 adenomas with neoplastic changes.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


90. Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC: Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res; 2005 Apr;124(2):169-74
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The study population was patients (n = 574, 67.1 +/- 11.3 years old, 397 males) who received potentially curative resection of colorectal adenocarcinoma (stage I-III) between January 1994 and August 2002, including preoperative measurements of CEA and CA19-9.
  • However, the combined use of the two markers revealed a significant survival benefit (P = 0.035) of group 1 ("-" for both markers) over 4 ("+" for both) in stage II.
  • CONCLUSIONS: Patients with an elevated level of both CEA and CA19-9 in stage II of colorectal cancer have a significantly poorer prognosis than those with normal levels of these markers.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820244.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


91. Childs AJ, Burke JJ 2nd, Perry MY, Check WE, Gallup DG: Recurrent colorectal carcinoma detected by routine cervicovaginal papanicolaou smear testing. J Low Genit Tract Dis; 2005 Oct;9(4):236-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We present a case of recurrent colon cancer detected by routine, annual Papanicolaou screening.
  • CASE: A 59-year-old African American woman who had been treated for T2N0M0 (stage II, Dukes A) colon cancer 2 years before to presentation had a Pap smear showing a high-grade squamous intraepithelial lesion with a normal cervical biopsy result.
  • Because of this discrepancy, a loop electrosurgical excision procedure and endocervical curettage were performed and showed atypical glandular cells suspicious for adenocarcinoma.
  • Subsequent colonoscopy showed recurrent adenocarcinoma of the colon.
  • The patient underwent an en-block total abdominal hysterectomy and anterior-perineal resection showing invasion of recurrent colon cancer into the uterus and cervix.
  • CONCLUSION: In patients with a history of extrauterine adenocarcinoma, abnormal Pap screening may indicate recurrent or metastatic carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colorectal Neoplasms / diagnosis. Diagnostic Tests, Routine. Neoplasm Recurrence, Local / diagnosis. Papanicolaou Test. Uterine Neoplasms / diagnosis. Vaginal Smears


92. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with adenocarcinoma underwent preoperative endorectal ultrasound to individualize for neoadjuvant chemoradiotherapy, based on local extent and lymph nodes seen.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • At a median follow-up of 14 (2-33) months, none of the adenocarcinoma patients who had undergone curative resection had recurrences.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


93. Liu YL, Matsuzaki T, Nakazawa T, Murata S, Nakamura N, Kondo T, Iwashina M, Mochizuki K, Yamane T, Takata K, Katoh R: Expression of aquaporin 3 (AQP3) in normal and neoplastic lung tissues. Hum Pathol; 2007 Jan;38(1):171-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In normal lung tissues, immunohistochemical expression of AQP3 was demonstrated in bronchial basal cells, alveolar type II cells, bronchiolar epithelial cells, and secretory cells of submucosal glands.
  • No AQP3 expression was demonstrated in small cell carcinoma, pleomorphic carcinoma, or metastatic colon adenocarcinoma.
  • In addition, AQP3 expression was related to tumor differentiation and clinical stage in adenocarcinomas.
  • Western blotting and reverse transcriptase-polymerase chain reaction analyses confirmed the expression of AQP3 protein and messenger RNA in cell lines and tissues of lung adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Blotting, Western. Cell Line, Tumor. Female. Gene Expression. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056099.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 158801-98-0 / Aquaporin 3
  •  go-up   go-down


94. Brosens RP, Oomen JL, Glas AS, van Bochove A, Cuesta MA, Engel AF: POSSUM predicts decreased overall survival in curative resection for colorectal cancer. Dis Colon Rectum; 2006 Jun;49(6):825-32
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 542 patients survived a radical resection for Stages I, II, or III colorectal cancer.
  • Differences in overall survival also were found when patients in Stages I, II, and III were analyzed separately.
  • Risk factors for overall survival were advanced stage of disease, poor tumor differentiation, mucinous adenocarcinoma, older than age 70 years, and poor condition of the patient at time of operation.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / surgery. Colorectal Neoplasms / mortality. Colorectal Neoplasms / surgery. Severity of Illness Index

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550320.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Liang JT, Lai HS, Lee PH: Multimedia article. Laparoscopic abdominoperineal resection for lower rectal cancers: how do we do it? Surg Endosc; 2006 Apr;20(4):695-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The appropriateness of the laparoscopic approach for the resection of rectal cancer has been controversial, although it is well established in colon cancer.
  • This is a phase II study of laparoscopic abdominoperineal resection (APR) in the treatment of lower rectal cancers.
  • METHODS: Patients with lower rectal adenocarcinoma located within 6 cm above the anal verge were recruited and subjected to laparoscopic APR.
  • Physical status (American Society of Anesthesiology classification) was class I in 12, class II in eight, and class III in two patients.
  • Two patients were in pathologic TNM stage I, 14 in stage II, and six in stage III.
  • [MeSH-major] Abdomen / surgery. Adenocarcinoma / surgery. Laparoscopy / methods. Perineum / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Dis Colon Rectum. 2002 Nov;45(11):1481-5 [12432295.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):46-54; discussion 54-5 [9660024.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2000 Feb;10(1):47-53 [10706303.001]
  • [Cites] World J Surg. 2003 Feb;27(2):190-6 [12616435.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • (PMID = 16502195.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Video-Audio Media
  • [Publication-country] Germany
  •  go-up   go-down


96. Yamada K, Ogata S, Saiki Y, Fukunaga M, Tsuji Y, Takano M: Long-term results of intersphincteric resection for low rectal cancer. Dis Colon Rectum; 2009 Jun;52(6):1065-71
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The five-year disease-free survival rates classified according to the TNM stage were 100 percent for stage I, 83.5 percent for stage II, and 72.0 percent for stage III cases.
  • [MeSH-major] Adenocarcinoma / surgery. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581848.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Bachet JB, Rougier P, de Gramont A, André T: [Rectal cancer and adjuvant chemotherapy: which conclusions?]. Bull Cancer; 2010 Jan;97(1):107-22
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cancer du rectum et chimiothérapie adjuvante: quelles conclusions?
  • Adenocarcinoma of the rectum represents about a third of cases of colorectal cancer, with an annual incidence of 12,000 cases in France.
  • On the contrary of colon cancer, the benefice of adjuvant chemotherapy in rectal cancer has not been definitively proved, more because this question was assessed in few recent studies than because negative results.
  • The data of the "historical studies" of adjuvant treatment in rectal cancer published before 1990, of the meta-analysis of adjuvant trials in rectal cancer and of the QUASAR study suggest that adjuvant chemotherapy with fluoropyrimidines (intravenous or oral), in absence of pre-operative treatment, decrease the risk of metastatic relapse after curative surgery for a rectal cancer of stage II or III.
  • This benefice seems similar to the one observed in colon cancer.
  • The French recommendations are to discuss the indication of adjuvant chemotherapy by fluoropyrimidines in cases of stage III rectal cancer on histopathologic reports and no chemotherapy in case of stade II.
  • Despite the fact that none study have assessed a combination of fluoropyrimidines and oxaliplatin in adjuvant setting in rectal cancer, like in colon cancer, the Folfox4, modified Folfox6 or Xelox regimens are valid options in stage III (experts opinion).
  • [MeSH-major] Adenocarcinoma / drug therapy. Rectal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965305.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 58
  •  go-up   go-down


98. Lim SB, Choi HS, Jeong SY, Park JG: Feasibility of laparoscopic techniques as the surgical approach of choice for primary colorectal cancer: an analysis of 570 consecutive cases. Surg Endosc; 2008 Dec;22(12):2588-95
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The study times were divided into three periods based on the COST trial report and the time when the laparoscopic technique was accepted as the surgical approach of choice at our center (period I: October 2000 to May 2004, II: June 2004 to December 2005, III: January to December 2006).
  • RESULTS: The use of laparoscopic surgery increased from 2.4% in period I, to 19.2% in period II, to 66.1% in period III.
  • Over the periods, the proportion of rectal cancer and right colon cancer increased (p < 0.001), T- and N-stage became more advanced (p < 0.001, p = 0.011 respectively), and operative time decreased (p < 0.001).
  • The short-term favorable outcomes support the feasibility of laparoscopic technique as surgical approach of choice for colon cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2010 Mar;24(3):726-7 [19633895.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Surg Endosc. 2003 Apr;17(4):636-40 [12574925.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Arch Surg. 1997 Jan;132(1):41-4; discussion 45 [9006551.001]
  • [Cites] Dis Colon Rectum. 2002 Dec;45(12):1648-54 [12473889.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Surg Laparosc Endosc. 1991 Sep;1(3):144-50 [1688289.001]
  • [Cites] Br J Surg. 2004 Sep;91(9):1111-24 [15449261.001]
  • [Cites] Surg Endosc. 2006 Aug;20(8):1197-202 [16865622.001]
  • [Cites] Ann Surg. 2005 Jul;242(1):83-91 [15973105.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1239-48 [16873440.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):759-66; disscussion 767 [12454514.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Colorectal Dis. 2005 Jul;7(4):369-74 [15932561.001]
  • [Cites] Dis Colon Rectum. 1997 May;40(5):592-6 [9152190.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Ann Surg. 2002 Apr;235(4):449-57 [11923599.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):116-20 [11285950.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • [Cites] Dis Colon Rectum. 1995 Jun;38(6):600-3 [7774470.001]
  • (PMID = 19011948.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


99. Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K: Nuclear S100A4 is a novel prognostic marker in colorectal cancer. Eur J Cancer; 2010 Nov;46(16):2919-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two hundred and forty two patients with curatively resected adenocarcinoma of the colon or rectum were prospectively included in the study at the time of surgery.
  • Interestingly, the prognostic impact was largely confined to TNM stage II, and stage II patients with tumours expressing nuclear S100A4 had a similar prognosis as stage III patients.
  • In conclusion, nuclear expression of S100A4 is a novel prognostic marker in colorectal cancer, and the prognostic value in TNM stage II suggests that nuclear S100A4 could be used in the stratification of stage II patients for adjuvant treatment.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Colonic Neoplasms / diagnosis. Rectal Neoplasms / diagnosis. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20719498.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


100. Thirunavukarasu P, Sathaiah M, Singla S, Sukumar S, Karunamurthy A, Pragatheeshwar KD, Lee KK, Zeh H 3rd, Kane KM, Bartlett DL: Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol; 2010 Oct;37(4):901-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Medullary carcinoma (MC) of the colorectum is a relatively new histological type of adenocarcinoma characterized by poor glandular differentiation and intraepithelial lymphocytic infiltrate.
  • We observed that MCs were rare tumors, constituting approximately 5-8 cases for every 10,000 colon cancers diagnosed, with a mean annual incidence of 3.47 (+/-0.75) per 10 million population.
  • MCs were twice as common in females, who presented at a later age, with a lower stage and a trend towards favorable prognosis.
  • MCs were most common in the proximal colon (74%), where they present at a later age than the sigmoid colon.
  • MCs commonly presented with Stage II disease, with 10% presenting with metastases.
  • Although MCs showed a trend towards better early overall survival, undifferentiated MCs present more commonly with Stage III, with comparatively worse early outcomes.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Medullary / epidemiology. Colorectal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2429-38 [10561306.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):527-35 [11159189.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2239-48 [11733373.001]
  • [Cites] Histopathology. 1977 Jan;1(1):77-84 [615835.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] J Clin Oncol. 2010 Jan 10;28(2):264-71 [19949014.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):843-8 [10414504.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):56-65 [15762280.001]
  • [Cites] Hum Pathol. 2009 Mar;40(3):398-404 [18992917.001]
  • [Cites] Oncology (Williston Park). 2009 Mar;23(3):288-95 [19418830.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1815-25 [9137104.001]
  • (PMID = 20811712.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA113263
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  • [Other-IDs] NLM/ NIHMS609288; NLM/ PMC4127912
  •  go-up   go-down






Advertisement